-
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2024 Dec 03.
Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ. PMID: 39625569.
View in:
PubMed Mentions:
-
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024 Dec; 25(12):e629-e638.
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. PMID: 39637900.
View in:
PubMed Mentions:
-
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Ann Oncol. 2024 Oct 28.
Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Veer LJV', Esserman L, Rugo HS. PMID: 39477071.
View in:
PubMed Mentions: Fields:
-
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Oncologist. 2024 Oct 17.
Brufsky A, Liu X, Li B, McRoy L, Chen C, Makari D, Layman RM, Rugo HS. PMID: 39418346.
View in:
PubMed Mentions: Fields:
-
Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care. Clin Breast Cancer. 2024 Sep 28.
Moore HN, Goncalves MD, Johnston AM, Mayer EL, Rugo HS, Gradishar WJ, Zylla DM, Bergenstal RM. PMID: 39462728.
View in:
PubMed Mentions: Fields:
-
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy. Breast Cancer Res Treat. 2024 Sep 21.
Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ. PMID: 39305392.
View in:
PubMed Mentions: Fields:
-
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer. Future Oncol. 2024 Sep 16; 1-13.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortés J, Gomez HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Murillo SM, Park YH, Sohn JH, Toi M, Tokunaga E, Yousef S, Zhukova L, Bruin E, Grinsted L, Schiavon G, Foxley A, Rugo HS. PMID: 39283299.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Sep 14.
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. PMID: 39277671.
View in:
PubMed Mentions:
1 Fields:
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Sep 14.
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. PMID: 39277672.
View in:
PubMed Mentions:
2 Fields:
-
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol. 2024 Sep 12; JCO2400920.
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B, TROPION-Breast01 Investigators. PMID: 39265124.
View in:
PubMed Mentions:
1 Fields:
-
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC. NPJ Breast Cancer. 2024 Sep 12; 10(1):79.
Im SA, Cortes J, Cescon DW, Yusof MM, Iwata H, Masuda N, Takano T, Huang CS, Chung CF, Tsugawa K, Park YH, Matsumoto K, Inoue K, Kwong A, Loi S, Fu W, Pan W, Karantza V, Rugo HS, Schmid P. PMID: 39266535; PMCID: PMC11393332.
View in:
PubMed Mentions:
-
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial. Oncologist. 2024 Sep 06; 29(9):768-779.
Rugo HS, Schmid P, Tolaney SM, Dalenc F, Marmé F, Shi L, Verret W, Shah A, Gharaibeh M, Bardia A, Cortes J. PMID: 38748596; PMCID: PMC11379636.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. ESMO Open. 2024 Sep; 9(9):103697.
Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, Logan J, Twomey K, Khatun M, D'Cruz CM, Turner NC. PMID: 39241495; PMCID: PMC11406080.
View in:
PubMed Mentions:
1 Translation:
HumansCTClinical Trials
-
Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes. J Clin Invest. 2024 Sep 03; 134(17).
Winkler J, Tan W, Diadhiou CM, McGinnis CS, Abbasi A, Hasnain S, Durney S, Atamaniuc E, Superville D, Awni L, Lee JV, Hinrichs JH, Wagner PS, Singh N, Hein MY, Borja M, Detweiler AM, Liu SY, Nanjaraj A, Sitarama V, Rugo HS, Neff N, Gartner ZJ, Oliveira Pisco A, Goga A, Darmanis S, Werb Z. PMID: 39225101; PMCID: PMC11364385.
View in:
PubMed Mentions: Fields:
Translation:
HumansAnimalsCells
-
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2024 Sep; 25(9):1231-1244.
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC, CAPItello-291 study group. PMID: 39214106.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCTClinical Trials
-
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502. NPJ Breast Cancer. 2024 Aug 21; 10(1):75.
Stover DG, Salgado R, Savenkov O, Ballman K, Mayer EL, Magbanua MJM, Loi S, Vater M, Glover K, Watson M, Wen Y, Symmans WF, Perou C, Carey LA, Partridge AH, Rugo HS. PMID: 39169033; PMCID: PMC11339397.
View in:
PubMed Mentions:
-
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med. 2024 Aug; 30(8):2371.
Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. PMID: 38914862; PMCID: PMC11333270.
View in:
PubMed Mentions: Fields:
-
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply. Lancet. 2024 Jul 27; 404(10450):339-340.
Rugo HS, Bardia A, Tolaney S. PMID: 39067902.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study. Future Oncol. 2024; 20(28):2037-2048.
Johnston SRD, Rugo HS, Tolaney SM, Munoz Fernandez M, Wei R, Martin M. PMID: 39023253; PMCID: PMC11500823.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer. 2024 Oct 01; 130(19):3251-3271.
Elghazaly H, Azim HA, Rugo HS, Cameron D, Swain SM, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, El Saghir NS, Penault-Llorca F, Perez EA, Poortmans P, Abdelaziz H, El-Zawahry HM, Kassem L, Sabry M, Viale G, Al-Sukhun S, Gado N, Leung JWT, Ezz Elarab L, Cardoso MJ, Abdel Karim K, Foheidi M, Elmaadawy MM, Conte P, Selim ASM, Kandil A, Kamal RM, Paltuev RM, Guarneri V, Abulkhair O, Zakaria O, Golshan M, Orecchia R, ElMahdy M, Abdel-Aziz AM, Eldin NB. PMID: 38985794.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024 Jul 09; 10(1):55.
Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, Diéras V, Phan S, Delaney R, Zhu Y, Tolaney SM. PMID: 38982075; PMCID: PMC11233646.
View in:
PubMed Mentions:
-
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 07; 22(5):331-357.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R. PMID: 39019058.
View in:
PubMed Mentions:
12 Fields:
Translation:
Humans
-
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies. NPJ Breast Cancer. 2024 Jun 29; 10(1):54.
Cheang MCU, Rimawi M, Johnston S, Jacobs SA, Bliss J, Pogue-Geile K, Kilburn L, Zhu Z, Schuster EF, Xiao H, Swaim L, Deng S, Lu DR, Gauthier E, Tursi J, Slamon DJ, Rugo HS, Finn RS, Liu Y. PMID: 38951507; PMCID: PMC11217366.
View in:
PubMed Mentions:
-
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024 Nov; 42(31):3652-3665.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM, Consortium of the TBCRC Translational Investigators, TBCRC Translational Investigators. PMID: 38935923; PMCID: PMC11527383.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future Oncol. 2024; 20(31):2343-2355.
Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W, Sun SW, Mocci S, Partridge AH, Carey LA. PMID: 38922307; PMCID: PMC11520537.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study. Breast Cancer Res Treat. 2024 Aug; 206(3):625-636.
Huppert LA, Fisch S, Tsopurashvili E, Somepalle SS, Salans M, Vasudevan HN, Jo Chien A, Majure M, Rugo HS, Balassanian R, Boreta L, Melisko ME. PMID: 38888796; PMCID: PMC11208257.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5. J Clin Oncol. 2024 Aug 01; 42(22):2680-2690.
Cortés J, Hurvitz SA, O'Shaughnessy J, Delaloge S, Iwata H, Rugo HS, Neven P, Kanagavel D, Cohen P, Paux G, Cartot-Cotton S, Stefanova-Urena M, Deyme L, Aouni J, Sebastien B, Bardia A. PMID: 38889373.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024 Jun 06; 10(1):41.
Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cortés J, Diéras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K. PMID: 38844800; PMCID: PMC11156627.
View in:
PubMed Mentions:
-
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B. ESMO Open. 2024 Jun; 9(6):103466.
Marmé F, Martin M, Untch M, Thode C, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, García-Sáenz JA, Kelly CM, Reimer T, Valota O, Toi M, Rugo HS, Gnant M, Makris A, Bassy M, Zhang Z, Furlanetto J, Nekljudova V, Loibl S. PMID: 38838498; PMCID: PMC11190462.
View in:
PubMed Mentions:
2 Translation:
HumansCTClinical Trials
-
68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG. J Nucl Med. 2024 Jun 03; 65(6):938-943.
Kline B, Yadav S, Seo Y, Ippisch RC, Castillo J, Aggarwal RR, Kelley RK, Behr SC, Flavell RR, Lawhn-Heath C, Melisko M, Rugo HS, Wang V, Yom SS, Ha P, Jiang F, Hope TA. PMID: 38697672; PMCID: PMC11149593.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2444-2451.
Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. PMID: 38470545; PMCID: PMC11147708.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med. 2024 Aug; 30(8):2242-2250.
Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. PMID: 38824244; PMCID: PMC11333285.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCTClinical Trials
-
Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary. Future Oncol. 2024; 20(19):1309-1317.
Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. PMID: 38536033; PMCID: PMC11333972.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024 Aug; 76:103756.
Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, Bajpai J, Barrios CH, Bergh J, Bergsten-Nordström E, Biganzoli L, Cardoso MJ, Carey LA, Chavez-MacGregor M, Chidebe R, Cortés J, Curigliano G, Dent RA, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Franco Millan SX, Gilchrist J, Gligorov J, Gradishar WJ, Haidinger R, Harbeck N, Hu X, Kaur R, Kiely B, Kim SB, Koppikar S, Kuper-Hommel MJJ, Lecouvet FE, Mason G, Mertz SA, Mueller V, Myerson C, Neciosup S, Offersen BV, Ohno S, Pagani O, Partridge AH, Penault-Llorca F, Prat A, Rugo HS, Senkus E, Sledge GW, Swain SM, Thomssen C, Vorobiof DA, Vuylsteke P, Wiseman T, Xu B, Costa A, Norton L, Winer EP. PMID: 38896983; PMCID: PMC11231614.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. J Natl Cancer Inst. 2024 May 08; 116(5):717-727.
Cescon DW, Schmid P, Rugo HS, Im SA, Md Yusof M, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Haiderali A, Zhou X, Guo Z, Nguyen AM, Cortes J. PMID: 38070159.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ Breast Cancer. 2024 Apr 26; 10(1):34.
Goetz MP, Cicin I, Testa L, Tolaney SM, Huober J, Guarneri V, Johnston SRD, Martin M, Rastogi P, Harbeck N, Shahir A, Wei R, André V, Rugo HS, O'Shaughnessy J. PMID: 38671001; PMCID: PMC11053007.
View in:
PubMed Mentions:
1
-
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024 Apr 25; 10(1):33.
Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, Diéras V, Phan S, Delaney R, Zhu Y, Tolaney SM. PMID: 38664404; PMCID: PMC11045722.
View in:
PubMed Mentions:
5
-
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer. J Clin Oncol. 2024 Aug 01; 42(22):2632-2636.
Ríos-Hoyo A, Cobain E, Huppert LA, Beitsch PD, Buchholz TA, Esserman L, van 't Veer LJ, Rugo HS, Pusztai L. PMID: 38593393.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024 Apr; 25(4):474-487.
Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R. PMID: 38547892.
View in:
PubMed Mentions:
6 Fields:
Translation:
HumansCTClinical Trials
-
Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs). Curr Ophthalmol Rep. 2024 Jun; 12(2):13-22.
Lindgren ES, Yan R, Cil O, Verkman AS, Chan MF, Seitzman GD, Farooq AV, Huppert LA, Rugo HS, Pohlmann PR, Lu J, Esserman LJ, Pasricha ND. PMID: 38756824; PMCID: PMC11095972.
View in:
PubMed Mentions:
-
The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncol Pract. 2024 Jul; 20(7):972-983.
Loeser A, Kim JS, Peppercorn J, Burkard ME, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. PMID: 38518184.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study. Future Oncol. 2024; 20(19):1299-1307.
Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Tomlin-Harris T, Brufsky A. PMID: 38517416; PMCID: PMC11333971.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer. Breast Cancer Res. 2024 03 04; 26(1):36.
Rodón J, Demanse D, Rugo HS, Burris HA, Simó R, Farooki A, Wellons MF, André F, Hu H, Vuina D, Quadt C, Juric D. PMID: 38439079; PMCID: PMC10913434.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20; 42(15):1738-1744.
Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA. PMID: 38422473; PMCID: PMC11107894.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. PMID: 38109213; PMCID: PMC10956403.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 2024 Mar; 25(3):317-325.
Palmieri C, Linden H, Birrell SN, Wheelwright S, Lim E, Schwartzberg LS, Dwyer AR, Hickey TE, Rugo HS, Cobb P, O'Shaughnessy JA, Johnston S, Brufsky A, Tilley WD, Overmoyer B. PMID: 38342115.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansCTClinical Trials
-
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncol. 2024 Feb; 25(2):e73-e83.
Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L, Consensus Panellist Group. PMID: 38301705.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative). Future Oncol. 2024 Apr; 20(11):635-651.
Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Spears PA, Tolaney SM. PMID: 38270051.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. J Clin Oncol. 2024 Mar 20; 42(9):994-1000.
Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS. PMID: 38252901; PMCID: PMC10950136.
View in:
PubMed Mentions:
16 Fields:
Translation:
Humans
-
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. J Clin Oncol. 2024 Mar 20; 42(9):987-993.
Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. PMID: 38194616; PMCID: PMC10950161.
View in:
PubMed Mentions:
20 Fields:
Translation:
Humans
-
Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer. Breast Cancer Res Treat. 2024 Apr; 204(3):509-520.
Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ. PMID: 38194132; PMCID: PMC10959837.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol. 2024 01; 10:e2300285.
Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El Saghir NS, Arun BK. PMID: 38206277; PMCID: PMC10793992.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials. Breast Cancer Res Treat. 2024 Apr; 204(2):249-259.
Rugo HS, Van Poznak CH, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Vega Alonso E, Naume B, Brain E, Siegel JM, Li R, Uema D, Wagner VJ, Coleman RE. PMID: 38123789; PMCID: PMC10948526.
View in:
PubMed Mentions:
3 Fields:
Translation:
HumansCTClinical Trials
-
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO). Radiother Oncol. 2024 06; 195:110060.
Kaidar-Person O, Meattini I, Boersma LJ, Becherini C, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Rugo HS, Del Mastro L, Gennari A, Isacke CM, Vestmø Maraldo M, Marangoni E, Nader Marta G, Mjaaland I, Salvestrini V, Spanic T, Visani L, Morandi A, Lambertini M, Livi L, Coles CE, Poortmans P, Offersen BV. PMID: 38122852.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer? Clin Cancer Res. 2023 12 15; 29(24):4993-4995.
Huppert LA, Rugo HS. PMID: 37782311.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer. Ther Adv Med Oncol. 2023; 15:17588359231216095.
Jhaveri K, O'Shaughnessy J, Fasching PA, Tolaney SM, Yardley DA, Sharma VK, Biswas C, Thuerigen A, Pathak P, Rugo HS. PMID: 38107828; PMCID: PMC10722948.
View in:
PubMed Mentions:
2
-
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Rep Med. 2023 12 19; 4(12):101312.
Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF. PMID: 38086377; PMCID: PMC10772394.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol. 2023 12; 34(12):1141-1151.
Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, Graff SL, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard TJ, Rugo HS, Sammons SL, Schwartzberg LS, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Gal-Yam EN. PMID: 38072514.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansCTClinical Trials
-
Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician's perspective. Clin Adv Hematol Oncol. 2023 Dec; 21(12):623-632.
Rugo HS. PMID: 38039056.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study. Eur J Cancer. 2024 Jan; 196:113420.
García-Sáenz JA, Marmé F, Untch M, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, Martin M, Kelly CM, Reimer T, Toi M, Law E, Bhattacharyya H, Gnant M, Makris A, Seiler S, Burchardi N, Nekljudova V, Loibl S, Rugo HS. PMID: 38000218.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results. Future Oncol. 2024 Jan; 20(1):5-16.
Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. PMID: 37916267.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice. Cancers (Basel). 2023 Nov 02; 15(21).
Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. PMID: 37958441; PMCID: PMC10649131.
View in:
PubMed Mentions:
-
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer. NPJ Breast Cancer. 2023 Oct 26; 9(1):88.
Record H, Clelland E, Rothschild HT, Kaur M, Chien AJ, Melisko M, Rugo HS, Mujir F, Huppert L, Mukhtar RA. PMID: 37884561; PMCID: PMC10603127.
View in:
PubMed Mentions:
1
-
Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database. Int J Cancer. 2024 Feb 15; 154(4):701-711.
Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. PMID: 37831416.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Jan; 203(2):197-204.
Gumusay O, Huppert LA, Magbanua MJM, Wabl CA, Assefa M, Chien AJ, Melisko ME, Majure MC, Moasser M, Park J, Rugo HS. PMID: 37815684; PMCID: PMC10787873.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. NPJ Breast Cancer. 2023 Oct 06; 9(1):81.
Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Hopkins JF, Albacker LA, Chelliserry J, Chen Y, Conte U, Wardley AM, Robson ME. PMID: 37803017; PMCID: PMC10558443.
View in:
PubMed Mentions:
2
-
Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey. Oncologist. 2023 10 03; 28(10):856-865.
Cardoso F, Rihani J, Harmer V, Harbeck N, Casas A, Rugo HS, Fasching PA, Moore A, de Courcy J, Pathak P, Haftchenary S, Aubel D, Schumacher-Wulf E. PMID: 37523663; PMCID: PMC10546820.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer. Oncologist. 2023 10 03; 28(10):866-874.
Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. PMID: 37487056; PMCID: PMC10546832.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol. 2023; 13:1237751.
Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. PMID: 37841423; PMCID: PMC10569486.
View in:
PubMed Mentions:
6
-
Glutaminase (GLS1) gene expression in primary breast cancer. Breast Cancer. 2023 Nov; 30(6):1079-1084.
Vidula N, Yau C, Rugo HS. PMID: 37679553.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 10 21; 402(10411):1423-1433.
Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Gómez Pardo P, Jhaveri KL, Delaney R, Valdez T, Wang H, Motwani M, Yoon OK, Verret W, Tolaney SM. PMID: 37633306.
View in:
PubMed Mentions:
57 Fields:
Translation:
HumansCTClinical Trials
-
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. J Clin Oncol. 2023 09 20; 41(27):4433-4442.
Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, Amiri-Kordestani L, Basho RK, Best AF, Boileau JF, Denkert C, Foster JC, Harbeck N, Jacene HA, King TA, Mason G, O'Sullivan CC, Prowell TM, Richardson AL, Sepulveda KA, Smith ML, Tjoe JA, Turashvili G, Woodward WA, Butler LP, Schwartz EI, Korde LA. PMID: 37433103; PMCID: PMC10522109.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis. Radiother Oncol. 2023 09; 186:109805.
Salvestrini V, Kim K, Caini S, Alkner S, Ekholm M, Skyttä T, Becherini C, Coles CE, Kaidar-Person O, Offersen B, de Azambuja E, Visani L, Cortes J, Harbeck N, Rugo HS, Isacke CM, Marangoni E, Morandi A, Lambertini M, Poortmans P, Livi L, Meattini I. PMID: 37437610.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer. Clin Breast Cancer. 2023 10; 23(7):721-728.
Jacob S, Johnson M, Roque B, Quintal L, Rugo HS, Melisko M, Chien AJ. PMID: 37474374.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCTClinical Trials
-
Bridging the "Know-Do" Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science. J Healthc Leadersh. 2023; 15:103-119.
Donohue JF, Elborn JS, Lansberg P, Javed A, Tesfaye S, Rugo H, Duddi SRD, Jithoo N, Huang PH, Subramaniam K, Ramanjinappa N, Koltun A, Melamed S, Chan JCN. PMID: 37416849; PMCID: PMC10320809.
View in:
PubMed Mentions:
10
-
Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: breast cancer. Clin Adv Hematol Oncol. 2023 07; 21(7):352-354.
Rugo HS. PMID: 37477992.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Future Oncol. 2024 Mar; 20(8):423-436.
Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. PMID: 37387213.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis. Cancer Treat Rev. 2023 Sep; 119:102586.
Becherini C, Visani L, Caini S, Bhattacharya IS, Kirby AM, Nader Marta G, Morgan G, Salvestrini V, Coles CE, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Isacke CM, Kaidar-Person O, Marangoni E, Offersen B, Rugo HS, Morandi A, Lambertini M, Poortmans P, Livi L, Meattini I. PMID: 37336117.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease. Breast Cancer Res. 2023 06 12; 25(1):67.
Schmid P, Cortes J, Joaquim A, Jañez NM, Morales S, Díaz-Redondo T, Blau S, Neven P, Lemieux J, García-Sáenz JÁ, Hart L, Biyukov T, Baktash N, Massey D, Burris HA, Rugo HS. PMID: 37308971; PMCID: PMC10258741.
View in:
PubMed Mentions:
6 Fields:
Translation:
HumansCTClinical Trials
-
Clinical course of multiple sclerosis and patient experiences during breast cancer treatment. Mult Scler. 2023 07; 29(8):967-978.
Nylander AN, Singh J, Poole S, Anderson A, Marrie RA, Rugo H, Bove R. PMID: 37291903; PMCID: PMC10338705.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023 Jun 01; 388(22):2058-2070.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS, CAPItello-291 Study Group. PMID: 37256976; PMCID: PMC11335038.
View in:
PubMed Mentions:
98 Fields:
Translation:
HumansCTClinical Trials
-
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023 06; 21(6):594-608.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Schneider B, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Young JS, Yeung K, Dwyer MA, Kumar R. PMID: 37308117.
View in:
PubMed Mentions:
81 Fields:
Translation:
Humans
-
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. JCO Oncol Pract. 2023 08; 19(8):539-546.
Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, Westbrook KE, Buys SS. PMID: 37207306; PMCID: PMC10424906.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
Margetuximab in HER2-positive metastatic breast cancer. Future Oncol. 2023 May; 19(16):1099-1112.
Gradishar WJ, O'Regan R, Rimawi MF, Nordstrom JL, Rosales MK, Rugo HS. PMID: 37170847.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023 06 12; 41(6):1091-1102.e4.
Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. PMID: 37146605; PMCID: PMC10330514.
View in:
PubMed Mentions:
27 Fields:
Translation:
Humans
-
Impact of Prior Authorization on Patient Access to Cancer Care. Am Soc Clin Oncol Educ Book. 2023 May; 43:e100036.
Trapani D, Kraemer L, Rugo HS, Lin NU. PMID: 37220314.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease. NPJ Breast Cancer. 2023 Apr 07; 9(1):22.
Im KW, Huppert LA, Malevanchik L, Rugo HS, Combes AJ, Campbell MJ, Krummel MF, Melisko ME. PMID: 37029150; PMCID: PMC10082042.
View in:
PubMed Mentions:
2
-
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. JCO Precis Oncol. 2023 04; 7:e2200317.
Loi S, Salgado R, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS, De Laurentiis M, Nanda R, Iwata H, Awada A, Tan AR, Sun Y, Karantza V, Wang A, Huang L, Saadatpour A, Cristescu R, Yearley J, Lunceford J, Jelinic P, Adams S. PMID: 37099733.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer. Breast. 2023 Jun; 69:375-381.
Rugo HS, Liu X, Li B, McRoy L, Layman RM, Brufsky A. PMID: 37080011; PMCID: PMC10127113.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023 Sep-Oct; 73(5):480-515.
Huppert LA, Gumusay O, Idossa D, Rugo HS. PMID: 36939293.
View in:
PubMed Mentions:
33 Fields:
Translation:
Humans
-
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma. Clin Cancer Res. 2023 03 14; 29(6):1056-1067.
Rugo HS, Raskina K, Schrock AB, Madison RW, Graf RP, Sokol ES, Sivakumar S, Lee JK, Fisher V, Oxnard GR, Tukachinsky H. PMID: 36321996; PMCID: PMC10011882.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023 03; 24(3):273-285.
Tolaney SM, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo JGT, Weiss J, Wagle N, Partridge AH, Waks AG, Hudis CA, Krop IE, Burstein HJ, Prat A, Winer EP. PMID: 36858723.
View in:
PubMed Mentions:
34 Fields:
Translation:
HumansCTClinical Trials
-
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison. Ther Adv Med Oncol. 2023; 15:17588359231152843.
Rugo HS, Harmer V, O'Shaughnessy J, Jhaveri K, Tolaney SM, Cardoso F, Bardia A, Maheshwari VK, Tripathi S, Haftchenary S, Pathak P, Fasching PA. PMID: 36861085; PMCID: PMC9969464.
View in:
PubMed Mentions:
2
-
Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Semin Oncol. 2023 Feb-Apr; 50(1-2):7-10.
Ruddy KJ, Zahrieh D, He J, Waechter B, Holleran JL, Lewis LD, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo HS, Loprinzi C. PMID: 36693773; PMCID: PMC10247389.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCTClinical Trials
-
Role of Immunotherapy in Breast Cancer. JCO Oncol Pract. 2023 04; 19(4):167-179.
Jacob SL, Huppert LA, Rugo HS. PMID: 36608303.
View in:
PubMed Mentions:
19 Fields:
Translation:
Humans
-
Reply to G.-F. Li et al, K. Altundag, and N. SG et al. J Clin Oncol. 2023 03 10; 41(8):1631-1632.
Rugo HS, Bardia A, Tolaney SM. PMID: 36608309.
View in:
PubMed Mentions: Fields:
-
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. Br J Cancer. 2023 Jan; 128(2):400.
Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, Pierce KJ, Mutka SC, Wainberg ZA. PMID: 36697966; PMCID: PMC9902525.
View in:
PubMed Mentions: Fields:
-
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast. 2023 Feb; 67:94-101.
Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N, DiPrimeo D, McCulloch L, Hurvitz SA, Barcenas CH. PMID: 36702070; PMCID: PMC9982309.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 01; 24(1):77-90.
Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, André V, Harbeck N, Martin M, monarchE Committee Members. PMID: 36493792; PMCID: PMC11200328.
View in:
PubMed Mentions:
97 Fields:
Translation:
HumansCTClinical Trials
-
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. NPJ Breast Cancer. 2022 Dec 01; 8(1):128.
Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. PMID: 36456573; PMCID: PMC9715670.
View in:
PubMed Mentions:
5
-
Management of breast cancer diagnosed during pregnancy: global perspectives. Expert Rev Anticancer Ther. 2022 12; 22(12):1301-1308.
Bajpai J, Pathak R, Shylasree TS, Rugo HS. PMID: 36480337.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nat Commun. 2022 Nov 21; 13(1):7140.
Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A. PMID: 36414627; PMCID: PMC9681724.
View in:
PubMed Mentions: Fields:
-
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3. Breast. 2022 Dec; 66:324-331.
Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. PMID: 36463643; PMCID: PMC9720565.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study. J Immigr Minor Health. 2023 Jun; 25(3):624-633.
Borno HT, Kim MO, Tolstykh I, Lin A, Hong JC, Yousefi S, Zhang S, McKay RR, Harismendy O, Razavi P, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 36344859; PMCID: PMC9640901.
View in:
PubMed Mentions: Fields:
Translation:
HumansCells
-
Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study. NPJ Breast Cancer. 2022 Nov 05; 8(1):118.
Rugo HS, Kabos P, Beck JT, Jerusalem G, Wildiers H, Sevillano E, Paz-Ares L, Chisamore MJ, Chapman SC, Hossain AM, Chen Y, Tolaney SM. PMID: 36335120; PMCID: PMC9637121.
View in:
PubMed Mentions:
17
-
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. Br J Cancer. 2023 01; 128(1):30-41.
Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, Pierce KJ, Mutka SC, Wainberg ZA. PMID: 36335217; PMCID: PMC9814742.
View in:
PubMed Mentions:
11 Fields:
Translation:
HumansCTClinical Trials
-
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. J Clin Oncol. 2023 01 10; 41(2):198-205.
Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, Bachelot T, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Schwartz GN, Pluard TJ, Ricci F, Gwin WR, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Gal-Yam EN, Yerushalmi R, Fasching PA, Kaufman PA, Ashley EJ, Perez-Olle R, Hong S, Rosales MK, Gradishar WJ, SOPHIA Study Group. PMID: 36332179; PMCID: PMC9839304.
View in:
PubMed Mentions:
28 Fields:
Translation:
HumansCTClinical Trials
-
Reply to Z.R. McCaw et al. J Clin Oncol. 2023 02 20; 41(6):1323-1324.
Rugo HS, Umanzor GA, Kwan MR, Cutler DL. PMID: 36346667.
View in:
PubMed Mentions: Fields:
-
Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study. Breast Cancer Res Treat. 2023 Jan; 197(1):137-148.
Huppert LA, Walker Z, Li M, Kim MO, Callan J, Brandman D, Majure M, Melisko ME, Rugo HS, Behr S, Chien AJ. PMID: 36319907.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study. Ann Surg Oncol. 2022 Nov; 29(12):7750.
Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA. PMID: 35798896.
View in:
PubMed Mentions: Fields:
-
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer. Future Oncol. 2022 Oct 21.
Rugo HS, Cortes J, Barrios CH, Cabrera P, Xu B, Huang CS, Kim SB, Melisko M, Nanda R, Pienkowski T, Rapoport BL, Schwab R. PMID: 36268941.
View in:
PubMed Mentions:
1 Fields:
-
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. Eur J Cancer. 2023 01; 178:23-33.
Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cortés J, O'Shaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, Chang L, Shi L, Piccart MJ. PMID: 36379186; PMCID: PMC11195534.
View in:
PubMed Mentions:
11 Fields:
Translation:
Humans
-
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. Breast. 2022 Dec; 66:169-177.
Shastry M, Jacob S, Rugo HS, Hamilton E. PMID: 36302269; PMCID: PMC9614644.
View in:
PubMed Mentions:
33 Fields:
Translation:
HumansCTClinical Trials
-
Little Downside. Int J Radiat Oncol Biol Phys. 2022 Nov 15; 114(4):573.
Singer L, Rugo HS. PMID: 36244389.
View in:
PubMed Mentions: Fields:
-
First, do no harm: risk of secondary cancer after breast cancer treatment. Lancet Oncol. 2022 11; 23(11):1350-1352.
Rugo HS, Singer L. PMID: 36240804.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ Breast Cancer. 2022 Oct 11; 8(1):114.
Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A. PMID: 36220852; PMCID: PMC9553912.
View in:
PubMed Mentions:
45
-
Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). Breast Cancer Res Treat. 2022 Dec; 196(3):549-563.
Loeser AL, Gao L, Bardia A, Burkard ME, Kalinsky KM, Peppercorn J, Rugo HS, Carlson M, Cowden J, Glenn L, Maues J, McGlown S, Ni A, Padron N, Lustberg M. PMID: 36198984.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. Future Oncol. 2022 Oct; 18(33):3701-3711.
Goel S, Tan AR, Rugo HS, Aftimos P, Andric Z, Beelen A, Zhang J, Yi JS, Malik R, O'Shaughnessy J. PMID: 36135712.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022 Sep 21; 22(1):1002.
Fillbrunn M, Signorovitch J, André F, Wang I, Lorenzo I, Ridolfi A, Park J, Dua A, Rugo HS. PMID: 36131248; PMCID: PMC9490901.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial. Front Oncol. 2022; 12:886831.
Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi HR, Kim SB, Bear HD, McCarthy N, Gelmon KA, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Gnant M, Makris A, Burchardi N, Schwenkglenks M. PMID: 36132153; PMCID: PMC9484462.
View in:
PubMed Mentions:
1
-
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2022 Aug 29; 8(1):98.
Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cortés J, Diéras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K. PMID: 36038616; PMCID: PMC9424318.
View in:
PubMed Mentions:
22
-
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2022 10 10; 40(29):3365-3376.
Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Pardo PG, Jhaveri KL, Delaney R, Fu O, Lin L, Verret W, Tolaney SM. PMID: 36027558.
View in:
PubMed Mentions:
79 Fields:
Translation:
Humans
-
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. NPJ Precis Oncol. 2022 Aug 16; 6(1):56.
Zhu Z, Turner NC, Loi S, André F, Martin M, Diéras V, Gelmon KA, Harbeck N, Zhang C, Cao JQ, Yan Z, Lu DR, Wei P, VanArsdale TL, Rejto PA, Huang X, Rugo HS, Loibl S, Cristofanilli M, Finn RS, Liu Y. PMID: 35974168; PMCID: PMC9381541.
View in:
PubMed Mentions:
6
-
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clin Cancer Res. 2022 08 15; 28(16):3433-3442.
Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, André F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean MJ, Turner NC. PMID: 35552673; PMCID: PMC9662922.
View in:
PubMed Mentions:
68 Fields:
Translation:
HumansCTClinical Trials
-
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022 08; 7(4):100553.
Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. PMID: 35964548; PMCID: PMC9375150.
View in:
PubMed Mentions:
25 Translation:
Humans
-
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022 07 21; 387(3):217-226.
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P, KEYNOTE-355 Investigators. PMID: 35857659.
View in:
PubMed Mentions:
254 Fields:
Translation:
HumansCTClinical Trials
-
Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. J Clin Oncol. 2023 01 01; 41(1):65-74.
Rugo HS, Umanzor GA, Barrios FJ, Vasallo RH, Chivalan MA, Bejarano S, Ramírez JR, Fein L, Kowalyszyn RD, Kramer ED, Wang H, Kwan MR, Cutler DL, Oraxol Study Consortium Investigators. PMID: 35858154; PMCID: PMC9788977.
View in:
PubMed Mentions:
3 Fields:
Translation:
HumansCTClinical Trials
-
The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study. Ann Surg Oncol. 2022 Nov; 29(12):7739-7747.
Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA. PMID: 35810223; PMCID: PMC9550696.
View in:
PubMed Mentions:
7 Fields:
Translation:
Humans
-
The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. Cancer Discov. 2022 07 06; 12(7):1620-1624.
Morgan G, Agarwal N, Choueiri TK, Dizon DS, Hamilton EP, Markham MJ, Lewis M, Prowell TM, Rugo HS, Subbiah V, West HL. PMID: 35791692.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast Cancer Res Treat. 2022 Aug; 194(3):569-575.
Vidula N, Yau C, Rugo H. PMID: 35789445.
View in:
PubMed Mentions:
17 Fields:
Translation:
HumansCells
-
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 07 01; 8(7):1047-1052.
Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J, ATTAIN Investigators. PMID: 35552364; PMCID: PMC9100460.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. Nat Commun. 2022 06 27; 13(1):3671.
Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A. PMID: 35760778; PMCID: PMC9237085.
View in:
PubMed Mentions:
24 Fields:
Translation:
HumansAnimalsCells
-
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? Eur J Cancer. 2022 08; 171:25-42.
Corti C, Antonarelli G, Valenza C, Nicolò E, Rugo H, Cortés J, Harbeck N, Carey LA, Criscitiello C, Curigliano G. PMID: 35696887.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022 Jun 09; 8(1):72.
Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, Cortés J. PMID: 35680967; PMCID: PMC9184615.
View in:
PubMed Mentions:
24
-
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 07 07; 387(1):9-20.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA, DESTINY-Breast04 Trial Investigators. PMID: 35665782; PMCID: PMC10561652.
View in:
PubMed Mentions:
680 Fields:
Translation:
HumansCTClinical Trials
-
Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice. JCO Precis Oncol. 2022 06; 6:e2100473.
Bui TBV, Burgering BMT, Goga A, Rugo HS, van 't Veer LJ. PMID: 35666959.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 06; 20(6):691-722.
Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R. PMID: 35714673.
View in:
PubMed Mentions:
307 Fields:
Translation:
Humans
-
The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer. J Immunother Cancer. 2022 06; 10(6).
Hung JT, Chen IJ, Ueng SH, Huang CS, Chen SC, Chen MY, Lin YC, Lin CY, Campbell MJ, Rugo HS, Yu AL. PMID: 35732348; PMCID: PMC9226869.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis. Front Pharmacol. 2022; 13:886954.
Liao H, Pei W, Zhong J, Shao B, Liu X, Liu Y, Zhang J, Rugo HS, Li H. PMID: 35721183; PMCID: PMC9198062.
View in:
PubMed Mentions:
-
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 06 13; 40(6):609-623.e6.
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ. PMID: 35623341; PMCID: PMC9426306.
View in:
PubMed Mentions:
86 Fields:
Translation:
HumansCTClinical Trials
-
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022 Sep; 195(2):127-139.
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J. PMID: 35545724; PMCID: PMC9374646.
View in:
PubMed Mentions:
16 Fields:
Translation:
Humans
-
COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry. Oncologist. 2022 05 06; 27(5):398-406.
Borno HT, Kim MO, Hong JC, Yousefi S, Lin A, Tolstykh I, Zhang S, McKay RR, Harismendy O, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 35348771; PMCID: PMC9074994.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 08; 33(8):814-823.
Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L, I-SPY Consortium. PMID: 35513244.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. J Natl Compr Canc Netw. 2022 05; 20(5):436-442.
Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L. PMID: 35545171.
View in:
PubMed Mentions:
16 Fields:
Translation:
Humans
-
Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer. J Oncol. 2022; 2022:5899728.
Apple AC, Lindbergh CA, Landau SM, DeLuca A, Eberling JL, Jagust WJ, Kramer JH, Rugo HS, Heflin LH. PMID: 35469310; PMCID: PMC9034940.
View in:
PubMed Mentions:
-
Emerging treatment strategies for metastatic triple-negative breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221086916.
Huppert LA, Gumusay O, Rugo HS. PMID: 35422881; PMCID: PMC9003656.
View in:
PubMed Mentions:
13
-
The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases. Breast. 2022 Jun; 63:149-156.
Gumusay O, Huppert LA, Behr SC, Rugo HS. PMID: 35397256; PMCID: PMC8991318.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer. Clin Cancer Res. 2022 04 01; 28(7):1383-1390.
Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA. PMID: 35091441; PMCID: PMC9365365.
View in:
PubMed Mentions:
10 Fields:
Translation:
HumansCells
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022 06; 33(6):616-627.
Rugo HS, O'Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, Gumus M, Yamashita T, Im YH, Rastogi P, Zagouri F, Song C, Campone M, San Antonio B, Shahir A, Hulstijn M, Brown J, Zimmermann A, Wei R, Johnston SRD, Reinisch M, Tolaney SM, monarchE Committee Members. PMID: 35337972.
View in:
PubMed Mentions:
23 Fields:
Translation:
Humans
-
Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. Front Oncol. 2022; 12:802579.
Magbanua MJM, Gumusay O, Kurzrock R, van 't Veer LJ, Rugo HS. PMID: 35372077; PMCID: PMC8964955.
View in:
PubMed Mentions:
6
-
Risk-Based Screening for Cancer in Patients With Dermatomyositis: Toward a More Individualized Approach. JAMA Dermatol. 2022 03 01; 158(3):244-247.
Vaughan H, Rugo HS, Haemel A. PMID: 35107570.
View in:
PubMed Mentions:
4 Fields:
Translation:
HumansPHPublic Health
-
Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study. JMIR Cancer. 2022 Feb 25; 8(1):e31756.
Umashankar S, Mamounas ME, Matthys M, Hadeler EK, Wong EC, Hicks G, Hwang J, Chien AJ, Rugo HS, Hamolsky D, Esserman L, Melisko M. PMID: 35212641; PMCID: PMC8917438.
View in:
PubMed Mentions:
-
Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer. 2022 Feb 18; 8(1):23.
Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, Andrè F, Curigliano G. PMID: 35181659; PMCID: PMC8857212.
View in:
PubMed Mentions:
44
-
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18.
Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM. PMID: 35173164; PMCID: PMC8850608.
View in:
PubMed Mentions:
8
-
Reconceptualizing Risk-Benefit Assessment of Novel Cancer Therapies to Expand Global Access and Reduce Worldwide Mortality. JAMA Oncol. 2022 02 01; 8(2):203-204.
DeBoer RJ, Rugo HS, Shulman LN. PMID: 34882172.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022 04; 33(4):384-394.
Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo JP, Metzger O, Dunbar M, Symmans WF, Rastogi P, Sohn JH, Young R, Wright GS, Harkness C, McIntyre K, Yardley D, Loibl S. PMID: 35093516.
View in:
PubMed Mentions:
56 Fields:
Translation:
HumansCTClinical Trials
-
Immunotherapy toxicity: identification and management. Breast Cancer Res Treat. 2022 Feb; 192(1):1-17.
Gumusay O, Callan J, Rugo HS. PMID: 35015209; PMCID: PMC8841316.
View in:
PubMed Mentions:
30 Fields:
Translation:
Humans
-
Role of Fcγ receptors in HER2-targeted breast cancer therapy. J Immunother Cancer. 2022 01; 10(1).
Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD. PMID: 34992090; PMCID: PMC8739678.
View in:
PubMed Mentions:
47 Fields:
Translation:
Humans
-
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 Jan; 126(1):162.
Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. PMID: 34853435; PMCID: PMC8727676.
View in:
PubMed Mentions: Fields:
-
Harmonizing PD-L1 testing in metastatic triple negative breast cancer. Expert Opin Biol Ther. 2022 03; 22(3):345-348.
Giugliano F, Antonarelli G, Tarantino P, Cortes J, Rugo HS, Curigliano G. PMID: 34930070.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
A multidisciplinary approach to optimizing care of patients treated with alpelisib. Breast. 2022 Feb; 61:156-167.
Rugo HS, Lacouture ME, Goncalves MD, Masharani U, Aapro MS, O'Shaughnessy JA. PMID: 35016012; PMCID: PMC8749445.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Ann Oncol. 2022 03; 33(3):234-238.
Tarantino P, Burstein HJ, Lin NU, Krop IE, Winer EP, Schnitt SJ, Hamilton EP, Hurvitz SA, Rugo HS, Curigliano G, Tolaney SM. PMID: 34942341.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Does the cancer geriatric assessment (GA) introduce bias into clinical trials? Observations from 988 prospectively recruited patients. J Geriatr Oncol. 2022 05; 13(4):526-529.
Peil E, Williams GR, Rugo H, Woyach JA, Jatoi A, Le-Rademacher JG. PMID: 34920971.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022 01 20; 40(3):282-293.
Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL, PALLAS groups and investigators. PMID: 34874182; PMCID: PMC10476784.
View in:
PubMed Mentions:
59 Fields:
Translation:
HumansCTClinical Trials
-
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. J Natl Cancer Inst. 2021 11 29; 113(12):1733-1743.
Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Winer EP, Kockx MM, Peeters D, Chui SY, Lin JC, Nguyen-Duc A, Viale G, Molinero L, Emens LA. PMID: 34097070; PMCID: PMC8634452.
View in:
PubMed Mentions:
51 Fields:
Translation:
HumansCTClinical Trials
-
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. NPJ Breast Cancer. 2021 Nov 11; 7(1):142.
Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE, Loibl S, Stover DG. PMID: 34764307; PMCID: PMC8586340.
View in:
PubMed Mentions:
13
-
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428.
Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. PMID: 34741023; PMCID: PMC8571284.
View in:
PubMed Mentions:
31 Fields:
Translation:
Humans
-
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993. Ann Oncol. 2021 Dec; 32(12):1650.
Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. PMID: 34740469.
View in:
PubMed Mentions:
2 Fields:
-
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663.
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. PMID: 34529000; PMCID: PMC8446908.
View in:
PubMed Mentions:
36 Fields:
Translation:
Humans
-
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST? NPJ Breast Cancer. 2021 Oct 25; 7(1):139.
Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA. PMID: 34697300; PMCID: PMC8547221.
View in:
PubMed Mentions:
1
-
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021 12; 32(12):1475-1495.
Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. PMID: 34678411.
View in:
PubMed Mentions:
352 Fields:
Translation:
Humans
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021 12; 32(12):1571-1581.
Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, Sohn J, Guarneri V, Cortés J, Hamilton E, André V, Wei R, Barriga S, Sherwood S, Forrester T, Munoz M, Shahir A, San Antonio B, Nabinger SC, Toi M, Johnston SRD, O'Shaughnessy J, monarchE Committee Members. PMID: 34656740.
View in:
PubMed Mentions:
136 Fields:
Translation:
HumansCTClinical Trials
-
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 02; 126(2):265-274.
Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. PMID: 34616010; PMCID: PMC8770703.
View in:
PubMed Mentions:
10 Fields:
Translation:
HumansCTClinical Trials
-
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer. 2021 Oct 05; 7(1):131.
Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. PMID: 34611148; PMCID: PMC8492731.
View in:
PubMed Mentions:
13
-
Expert Discussion: Predictive Markers. Breast Care (Basel). 2021 Oct; 16(5):552-557.
Paradiso A, Codacci-Pisanelli G, Munzone E, Rugo HS, Heudel PE. PMID: 34720818; PMCID: PMC8543338.
View in:
PubMed Mentions:
-
The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews. Ann Oncol. 2021 12; 32(12):1552-1570.
Chan RJ, Crichton M, Crawford-Williams F, Agbejule OA, Yu K, Hart NH, de Abreu Alves F, Ashbury FD, Eng L, Fitch M, Jain H, Jefford M, Klemanski D, Koczwara B, Loh K, Prasad M, Rugo H, Soto-Perez-de-Celis E, van den Hurk C, Chan A, Multinational Association of Supportive Care in Cancer (MASCC) Survivorship Study Group. PMID: 34509615.
View in:
PubMed Mentions:
49 Fields:
Translation:
HumansCellsPHPublic Health
-
Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ Breast Cancer. 2021 Sep 06; 7(1):113.
Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, Moasser M, Magbanua M, Park JW, Rugo HS. PMID: 34489453; PMCID: PMC8421499.
View in:
PubMed Mentions:
9
-
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Rev Anticancer Ther. 2021 10; 21(10):1105-1124.
Jhaveri K, Burris Rd HA, Yap TA, Hamilton E, Rugo HS, Goldman JW, Dann S, Liu F, Wong GY, Krupka H, Shapiro GI. PMID: 34176404.
View in:
PubMed Mentions:
18 Fields:
Translation:
Humans
-
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncol. 2021 Oct 01; 17(30):3911-3924.
Bardia A, Hurvitz SA, Rugo HS, Brufsky A, Cortes J, Loibl S, Piccart M, Cowden J, Spears P, Carey LA. PMID: 34467774.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. Breast Cancer Res. 2021 08 23; 23(1):87.
Neven P, Rugo HS, Tolaney SM, Iwata H, Toi M, Goetz MP, Kaufman PA, Lu Y, Haddad N, Hurt KC, Sledge GW. PMID: 34425869; PMCID: PMC8381581.
View in:
PubMed Mentions:
14 Fields:
Translation:
HumansCTClinical Trials
-
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993. Ann Oncol. 2021 Oct; 32(10):1308.
Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. PMID: 34353668.
View in:
PubMed Mentions:
1 Fields:
-
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021 08 02; 113(8):1005-1016.
Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Nguyen-Duc A, Chui SY, Husain A, Winer EP, Adams S, Schmid P. PMID: 33523233; PMCID: PMC8328980.
View in:
PubMed Mentions:
126 Fields:
Translation:
HumansCells
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 08; 9(8).
Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. PMID: 34389617; PMCID: PMC8365813.
View in:
PubMed Mentions:
37 Fields:
Translation:
Humans
-
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3959-3977.
Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS. PMID: 34324367; PMCID: PMC8659999.
View in:
PubMed Mentions:
104 Fields:
Translation:
Humans
-
Sacituzumab Govitecan in Metastatic Breast Cancer. Reply. N Engl J Med. 2021 07 15; 385(3):e12.
Bardia A, Hurvitz SA, Rugo HS. PMID: 34260848.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. Oncologist. 2021 10; 26(10):827-834.
Spring LM, Nakajima E, Hutchinson J, Viscosi E, Blouin G, Weekes C, Rugo H, Moy B, Bardia A. PMID: 34176192; PMCID: PMC8488774.
View in:
PubMed Mentions:
23 Fields:
Translation:
Humans
-
Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply. Lancet. 2021 07 03; 398(10294):24-25.
Cortes J, Rugo HS, Guo Z, Karantza V, Schmid P. PMID: 34217393.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021 08; 32(8):983-993.
Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. PMID: 34272041.
View in:
PubMed Mentions:
163 Fields:
Translation:
Humans
-
RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4883-4897.
Koh SB, Ross K, Isakoff SJ, Melkonjan N, He L, Matissek KJ, Schultz A, Mayer EL, Traina TA, Carey LA, Rugo HS, Liu MC, Stearns V, Langenbucher A, Saladi SV, Ramaswamy S, Lawrence MS, Ellisen LW. PMID: 34168046; PMCID: PMC8416935.
View in:
PubMed Mentions:
8 Fields:
Translation:
HumansCells
-
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5.
Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. PMID: 34143979; PMCID: PMC11064785.
View in:
PubMed Mentions:
110 Fields:
Translation:
HumansCTClinical Trials
-
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2021 Jul; 188(2):369-377.
Rugo HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, Herson J, Koch HF, Loganathan S, Deodhar S, Marwah A, Manikhas A, Bondarenko I, Mukhametshina G, Nemsadze G, Parra JD, Abesamis-Tiambeng MLT, Baramidze K, Akewanlop C, Vynnychenko I, Sriuranpong V, Mamillapalli G, Roy S, Yanez Ruiz EP, Barve A, Fuentes-Alburo A, Waller CF. PMID: 34125340; PMCID: PMC8260531.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110.
Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SM. PMID: 34120223.
View in:
PubMed Mentions:
11 Fields:
Translation:
Humans
-
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. Oncologist. 2021 08; 26(8):e1339-e1346.
Rugo HS, Cristofanilli M, Loibl S, Harbeck N, DeMichele A, Iwata H, Park YH, Brufsky A, Theall KP, Huang X, McRoy L, Bananis E, Turner NC. PMID: 34037282; PMCID: PMC8342589.
View in:
PubMed Mentions:
16 Fields:
Translation:
Humans
-
A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes. Clin Cancer Res. 2021 08 15; 27(16):4486-4490.
Potter DA, Thomas A, Rugo HS. PMID: 34108186.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCellsPHPublic Health
-
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 09; 32(9):1148-1156.
Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA. PMID: 34116144.
View in:
PubMed Mentions:
102 Fields:
Translation:
HumansCTClinical Trials
-
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385.
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. PMID: 34077270.
View in:
PubMed Mentions:
55 Fields:
Translation:
Humans
-
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. Oncologist. 2021 07; 26(7):e1133-e1142.
Turner S, Chia S, Kanakamedala H, Hsu WC, Park J, Chandiwana D, Ridolfi A, Yu CL, Zarate JP, Rugo HS. PMID: 33909934; PMCID: PMC8265362.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCTClinical Trials
-
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. Cancers (Basel). 2021 May 08; 13(9).
Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H. PMID: 34066769; PMCID: PMC8125909.
View in:
PubMed Mentions:
7
-
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 05 01; 19(5):484-493.
Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R. PMID: 34794122.
View in:
PubMed Mentions:
135 Fields:
Translation:
Humans
-
Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. Breast Cancer Res Treat. 2021 Jun; 187(2):387-395.
Vidula N, Yau C, Rugo HS. PMID: 33913053.
View in:
PubMed Mentions:
4 Fields:
Translation:
HumansCells
-
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 04 22; 384(16):1529-1541.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS, ASCENT Clinical Trial Investigators. PMID: 33882206.
View in:
PubMed Mentions:
433 Fields:
Translation:
HumansCTClinical Trials
-
In Reply. Oncologist. 2021 07; 26(7):e1286-e1287.
Rugo HS, Huober J, Garcia-Saenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M. PMID: 33826783; PMCID: PMC8265353.
View in:
PubMed Mentions: Fields:
-
Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectr. 2021 06; 5(3).
Ligibel JA, Huebner L, Rugo HS, Burstein HJ, Toppmeyer DL, Anders CK, Ma C, Barry WT, Suman V, Carey LA, Partridge AH, Hudis CA, Winer EP. PMID: 33981951; PMCID: PMC8103727.
View in:
PubMed Mentions:
6 Fields:
Translation:
HumansCTClinical Trials
-
Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer. Clin Cancer Res. 2021 06 15; 27(12):3275-3277.
Rugo HS, Huppert L. PMID: 33837007.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. J Natl Cancer Inst. 2021 04 06; 113(4):443-452.
Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein HJ, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. PMID: 32770247; PMCID: PMC8023821.
View in:
PubMed Mentions:
23 Fields:
Translation:
HumansCells
-
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Apr 01; 7(4):603-608.
Filho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, Geyer CE, Bae J, Collier K, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans WF. PMID: 33599688; PMCID: PMC7893540.
View in:
PubMed Mentions:
32 Fields:
Translation:
HumansCTClinical Trials
-
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Apr 01; 7(4):573-584.
Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ, SOPHIA Study Group. PMID: 33480963; PMCID: PMC7823434.
View in:
PubMed Mentions:
154 Fields:
Translation:
HumansCTClinical Trials
-
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021 05 10; 39(14):1518-1530.
Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Koehler M, Huang-Bartelett C, Lechuga Frean MJ, Colleoni M, Werutsky G, Seiler S, Burchardi N, Nekljudova V, von Minckwitz G. PMID: 33793299.
View in:
PubMed Mentions:
96 Fields:
Translation:
HumansCTClinical Trials
-
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021 04; 22(4):489-498.
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. PMID: 33794206.
View in:
PubMed Mentions:
134 Fields:
Translation:
HumansCTClinical Trials
-
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. Breast. 2021 Aug; 58:18-26.
Rugo HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, Herson J, Koch HF, Loganathan S, Deodhar S, Marwah A, Manikhas A, Bondarenko I, Parra JD, Abesamis-Tiambeng MLT, Akewanlop C, Vynnychenko I, Sriuranpong V, Roy S, Yanez Ruiz EP, Barve A, Waller CF. PMID: 33892316; PMCID: PMC8091175.
View in:
PubMed Mentions:
3 Fields:
Translation:
HumansCTClinical Trials
-
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. J Clin Oncol. 2021 06 20; 39(18):2005-2015.
Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, André F. PMID: 33780274; PMCID: PMC8210974.
View in:
PubMed Mentions:
17 Fields:
Translation:
Humans
-
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021 03 24; 23(1):37.
DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. PMID: 33761995; PMCID: PMC7989035.
View in:
PubMed Mentions:
53 Fields:
Translation:
Humans
-
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clin Cancer Res. 2021 08 01; 27(15):4177-4185.
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S. PMID: 33722897; PMCID: PMC8487593.
View in:
PubMed Mentions:
43 Fields:
Translation:
HumansCTClinical Trials
-
An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target Oncol. 2021 05; 16(3):255-282.
Cortesi L, Rugo HS, Jackisch C. PMID: 33710534; PMCID: PMC8105250.
View in:
PubMed Mentions:
136 Fields:
Translation:
Humans
-
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. Oncologist. 2021 05; 26(5):e749-e755.
Finn RS, Rugo HS, Gelmon KA, Cristofanilli M, Colleoni M, Loi S, Schnell P, Lu DR, Theall KP, Mori A, Gauthier E, Bananis E, Turner NC, Diéras V. PMID: 33486783; PMCID: PMC8100571.
View in:
PubMed Mentions:
21 Fields:
Translation:
Humans
-
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021 Mar; 26(3):e522.
Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M. PMID: 33660385; PMCID: PMC7930407.
View in:
PubMed Mentions:
12 Fields:
-
Navigating a Path to Equity in Cancer Care: The Role of Patient Navigation. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:1-8.
Dixit N, Rugo H, Burke NJ. PMID: 33830828.
View in:
PubMed Mentions:
22 Fields:
Translation:
Humans
-
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Res Treat. 2021 Jul; 188(1):179-190.
Kaufman PA, Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Brufsky AM, Rugo HS, Cobleigh M, Swain SM, Tripathy D, Morris A, Antao V, Li H, Jahanzeb M. PMID: 33641083.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. J Comp Eff Res. 2021 04; 10(6):457-467.
Rugo HS, Haltner A, Zhan L, Tran A, Bananis E, Hooper B, Mitra D, Cameron C. PMID: 33626934.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. Breast Cancer Res Treat. 2021 May; 187(1):155-165.
Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A, Russo S, Krop IE. PMID: 33591468; PMCID: PMC8062601.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. Clin Breast Cancer. 2021 10; 21(5):e575-e583.
Jackisch C, Barcenas CH, Bartsch R, Palma JD, Glück S, Harbeck N, Macedo G, O'Shaughnessy J, Pistilli B, Ruiz-Borrego M, Rugo HS. PMID: 33678567.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO Glob Oncol. 2021 02; 7:162-172.
Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Pusztai L, Peeters M, Berchem G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G. PMID: 33529077; PMCID: PMC8081548.
View in:
PubMed Mentions:
26 Fields:
Translation:
HumansPHPublic Health
-
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021 02; 22(2):212-222.
Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M. PMID: 33460574.
View in:
PubMed Mentions:
88 Fields:
Translation:
HumansCTClinical Trials
-
Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum. Lancet Oncol. 2021 01; 22(1):27-28.
Dent R, Rugo HS. PMID: 33387495.
View in:
PubMed Mentions:
7 Fields:
Translation:
Humans
-
Highlights in metastatic breast cancer from the 2020 San Antonio Breast Cancer Symposium: commentary. Clin Adv Hematol Oncol. 2021 Jan; 19 Suppl 1(1):18-19.
Rugo HS. PMID: 33843912.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 12 05; 396(10265):1817-1828.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P, KEYNOTE-355 Investigators. PMID: 33278935.
View in:
PubMed Mentions:
754 Fields:
Translation:
HumansCTClinical Trials
-
A 4-Month Whole-Systems Ayurvedic Medicine Nutrition and Lifestyle Intervention Is Feasible and Acceptable for Breast Cancer Survivors: Results of a Single-Arm Pilot Clinical Trial. Glob Adv Health Med. 2020; 9:2164956120964712.
Dhruva A, Wu C, Miaskowski C, Hartogensis W, Rugo HS, Adler SR, Kaptchuk TJ, Kelkar R, Agarawal S, Vadodaria A, Garris E, Hecht FM. PMID: 33312762; PMCID: PMC7716077.
View in:
PubMed Mentions:
5
-
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021 02; 32(2):208-217.
André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pápai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS. PMID: 33246021.
View in:
PubMed Mentions:
215 Fields:
Translation:
Humans
-
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021 01; 26(1):e53-e65.
Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M. PMID: 32955138; PMCID: PMC7794176.
View in:
PubMed Mentions:
42 Fields:
Translation:
Humans
-
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clin Breast Cancer. 2021 02; 21(1):80-91.e7.
Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M, ExteNET Study Group. PMID: 33183970.
View in:
PubMed Mentions:
90 Fields:
Translation:
HumansCTClinical Trials
-
Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign? CA Cancer J Clin. 2021 01; 71(1):34-46.
Cinar P, Bold R, Bosslet BA, Bota DA, Burgess D, Chew HK, Cohen JG, Elquza E, Gold KA, Kamiya E, Karlan BY, McKay RR, Patel SP, Ternavan K, Welborn J, Yamamoto M, Rugo HS. PMID: 32997807; PMCID: PMC7537198.
View in:
PubMed Mentions:
9 Fields:
Translation:
HumansPHPublic Health
-
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020 12; 31(12):1623-1649.
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. PMID: 32979513; PMCID: PMC7510449.
View in:
PubMed Mentions:
524 Fields:
Translation:
Humans
-
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. J Natl Compr Canc Netw. 2020 Sep 01; 1-4.
Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS. PMID: 32871558; PMCID: PMC9730290.
View in:
PubMed Mentions:
17 Fields:
-
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. PMID: 32701140; PMCID: PMC7378873.
View in:
PubMed Mentions:
83 Fields:
Translation:
Humans
-
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 11; 31(11):1526-1535.
Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. PMID: 32828825; PMCID: PMC10649377.
View in:
PubMed Mentions:
134 Fields:
Translation:
HumansCellsCTClinical Trials
-
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1. Breast Cancer Res Treat. 2020 Nov; 184(1):161-172.
Rugo HS, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DA, Carter GC, Sheffield KM, Li L, Andre VAM, Li XI, Frenzel M, Huang YJ, Dickler MN, Tolaney SM. PMID: 32789591; PMCID: PMC7568708.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Res Treat. 2020 Nov; 184(1):23-35.
Finn RS, Cristofanilli M, Ettl J, Gelmon KA, Colleoni M, Giorgetti C, Gauthier E, Liu Y, Lu DR, Zhang Z, Bartlett CH, Slamon DJ, Turner NC, Rugo HS. PMID: 32783178; PMCID: PMC7568717.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCTClinical Trials
-
Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. Clin Pharmacol Ther. 2020 09; 108(3):625-634.
Chua KC, Xiong C, Ho C, Mushiroda T, Jiang C, Mulkey F, Lai D, Schneider BP, Rashkin SR, Witte JS, Friedman PN, Ratain MJ, McLeod HL, Rugo HS, Shulman LN, Kubo M, Owzar K, Kroetz DL. PMID: 32562552; PMCID: PMC7718413.
View in:
PubMed Mentions:
16 Fields:
Translation:
HumansCells
-
Oncological care organisation during COVID-19 outbreak. ESMO Open. 2020 08; 5(4).
Onesti CE, Rugo HS, Generali D, Peeters M, Zaman K, Wildiers H, Harbeck N, Martin M, Cristofanilli M, Cortes J, Tjan-Heijnen V, Hurvitz SA, Berchem G, Tagliamento M, Campone M, Bartsch R, De Placido S, Puglisi F, Rottey S, Müller V, Ruhstaller T, Machiels JP, Conte P, Awada A, Jerusalem G. PMID: 32847836; PMCID: PMC7451457.
-
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020 07 17; 11(1):3584.
Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. PMID: 32681091; PMCID: PMC7367885.
View in:
PubMed Mentions:
83 Fields:
Translation:
HumansCellsCTClinical Trials
-
Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. J Immunother Cancer. 2020 07; 8(2).
Huang CS, Yu AL, Tseng LM, Chow LWC, Hou MF, Hurvitz SA, Schwab RB, L Murray J, Chang HK, Chang HT, Chen SC, Kim SB, Hung JT, Ueng SH, Lee SH, Chen CC, Rugo HS. PMID: 32718986; PMCID: PMC7380846.
View in:
PubMed Mentions:
20 Fields:
Translation:
HumansCTClinical Trials
-
Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Clin Cancer Res. 2020 09 15; 26(18):4911-4920.
Magbanua MJM, Savenkov O, Asmus EJ, Ballman KV, Scott JH, Park JW, Dickler M, Partridge A, Carey LA, Winer EP, Rugo HS. PMID: 32586939; PMCID: PMC7501177.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCells
-
Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. Clin Cancer Res. 2020 09 15; 26(18):4743-4747.
Hafez N, Rugo HS, Tempero MA, Fox E, Reaman GH, Lyerly HK, Walker D, LoRusso PM. PMID: 32571790.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chin J Cancer Res. 2020 Jun; 32(3):370-382.
Li H, Liu R, Shao B, Ran R, Song G, Wang K, Shi Y, Liu J, Hu W, Chen F, Liu X, Zhang G, Zhao C, Jia R, Wang Q, Rugo HS, Zhang Y, Li G, Xu J. PMID: 32694901; PMCID: PMC7369176.
View in:
PubMed Mentions:
14
-
Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib. JCO Precis Oncol. 2020; 4.
Batalini F, Moulder SL, Winer EP, Rugo HS, Lin NU, Wulf GM. PMID: 32923889; PMCID: PMC7446424.
View in:
PubMed Mentions:
25 Fields:
-
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol. 2020 09; 31(9):1223-1230.
Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D, Chan A, CONTROL Study Investigators. PMID: 32464281.
View in:
PubMed Mentions:
46 Fields:
Translation:
HumansCTClinical Trials
-
The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. Adv Ther. 2020 07; 37(7):3059-3082.
Rugo HS, Jacobs I, Sharma S, Scappaticci F, Paul TA, Jensen-Pergakes K, Malouf GG. PMID: 32445185; PMCID: PMC7467409.
View in:
PubMed Mentions:
35 Fields:
Translation:
HumansAnimals
-
Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol. 2020 07 20; 38(21):2438-2453.
Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, Rugo HS, Schnipper HH, Smith TJ, Tan W, Loprinzi CL. PMID: 32432946.
View in:
PubMed Mentions:
189 Fields:
Translation:
Humans
-
Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab. Onco Targets Ther. 2020; 13:4385-4395.
Ran R, Huang W, Liu Y, Shao L, Liu X, Niu Y, Kong W, Bo S, Rugo HS, Lu S, Li H. PMID: 32547071; PMCID: PMC7245474.
View in:
PubMed Mentions:
4
-
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020 08; 31(8):1001-1010.
Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, Jurado JC, Juric D, Mayer I, Ciruelos EM, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lteif A, Miller M, Gaudenzi F, Loibl S. PMID: 32416251.
View in:
PubMed Mentions:
52 Fields:
Translation:
HumansCTClinical Trials
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Nath A, Huo D, Fleming GF, Ingle JN, Abramson VG, Morrow PK, Storniolo AM, Forero A, Van Poznak C, Liu MC, Chang JC, Merkel DE, Peppercorn JM, Rugo HS, Dees EC, Hahn OM, Hoffman PC, Rosner GL, Huang RS, Ratain MJ, Cox N, Olopade OI, Wolff AC, Dolan ME, Nanda R, Translational Breast Cancer Research Consortium (TBCRC). PMID: 32378051.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020 10 15; 147(8):2190-2198.
Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T. PMID: 32359091.
View in:
PubMed Mentions:
198 Fields:
Translation:
Humans
-
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. Am Soc Clin Oncol Educ Book. 2020 May; 40:e292-e308.
Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS. PMID: 32453634.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 05 01; 6(5):676-684.
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. PMID: 32053137; PMCID: PMC7058271.
View in:
PubMed Mentions:
297 Fields:
Translation:
HumansCTClinical Trials
-
Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival. Breast Cancer Res Treat. 2020 May; 181(1):23-29.
Mukhtar RA, Krings G, Chen YY, Mamounas ME, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Rugo H. PMID: 32240457.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 04; 18(4):452-478.
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R. PMID: 32259783.
View in:
PubMed Mentions:
396 Fields:
Translation:
Humans
-
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Future Oncol. 2020 Apr; 16(12):705-715.
Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q, Delaney RJ, Hafeez A, André F, Schmid P. PMID: 32223649.
View in:
PubMed Mentions:
49 Fields:
Translation:
HumansCTClinical Trials
-
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Res. 2020 03 12; 22(1):27.
Ettl J, Im SA, Ro J, Masuda N, Colleoni M, Schnell P, Bananis E, Lu DR, Cristofanilli M, Rugo HS, Finn RS. PMID: 32164785; PMCID: PMC7068918.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCTClinical Trials
-
MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. Cell Rep. 2020 03 10; 30(10):3368-3382.e7.
Rohrberg J, Van de Mark D, Amouzgar M, Lee JV, Taileb M, Corella A, Kilinc S, Williams J, Jokisch ML, Camarda R, Balakrishnan S, Shankar R, Zhou A, Chang AN, Chen B, Rugo HS, Dumont S, Goga A. PMID: 32160543; PMCID: PMC7085414.
View in:
PubMed Mentions:
23 Fields:
Translation:
HumansAnimalsCells
-
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. JAMA Surg. 2020 03 01; 155(3):e195410.
Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessy J, Rugo HS, Wolmark N, McKee MD, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE, Sikov WM, Untch M. PMID: 31913413; PMCID: PMC6990971.
View in:
PubMed Mentions:
54 Fields:
Translation:
HumansCTClinical Trials
-
Highlights from the 2019 San Antonio Breast Cancer Symposium. Clin Adv Hematol Oncol. 2020 Mar; 18(3):157-159.
Rugo HS. PMID: 32609664.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020 05; 31(5):582-589.
Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui SY, Rugo HS, Emens LA, Schmid P. PMID: 32178964.
View in:
PubMed Mentions:
40 Fields:
Translation:
HumansCTClinical Trials
-
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast Cancer Res. 2020 02 18; 22(1):22.
Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A, Translational Breast Cancer Research Consortium (TBCRC). PMID: 32070401; PMCID: PMC7027068.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansCellsCTClinical Trials
-
Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. J Clin Oncol. 2020 04 01; 38(10):1070-1080.
Stebbing J, Mainwaring PN, Curigliano G, Pegram M, Latymer M, Bair AH, Rugo HS. PMID: 32058846; PMCID: PMC7106981.
View in:
PubMed Mentions:
11 Fields:
Translation:
Humans
-
Using diagnosis codes in claims data to identify cohorts of breast cancer patients following initial treatment. Breast J. 2020 07; 26(7):1472-1474.
Franc BL, Thombley R, Luo Y, John Boscardin W, Rugo HS, Seidenwurm D, Dudley RA. PMID: 31960541; PMCID: PMC7369243.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clin Breast Cancer. 2020 06; 20(3):183-193.
Kittaneh M, Badve S, Caldera H, Coleman R, Goetz MP, Mahtani R, Mamounas E, Kalinsky K, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Traina T, Vogel C. PMID: 32014370.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw. 2020 01; 18(1):12-22.
Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. PMID: 31910384.
View in:
PubMed Mentions:
40 Fields:
Translation:
Humans
-
Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer. Technol Cancer Res Treat. 2020 Jan-Dec; 19:1533033819896331.
Liu XR, Zhang RY, Gong H, Rugo HS, Chen LB, Fu Y, Che JW, Tie J, Shao B, Wan FL, Kong WY, Song GH, Jiang HF, Xu GB, Li HP. PMID: 32129154; PMCID: PMC7057408.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Androgen receptor gene expression in primary breast cancer. NPJ Breast Cancer. 2019; 5:47.
Vidula N, Yau C, Wolf D, Rugo HS. PMID: 31840050; PMCID: PMC6904475.
View in:
PubMed Mentions:
16
-
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). J Clin Pharmacol. 2020 04; 60(4):444-452.
Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV. PMID: 31802506; PMCID: PMC7064382.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):44-59.
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Investigators. PMID: 31786121.
View in:
PubMed Mentions:
538 Fields:
Translation:
HumansCTClinical Trials
-
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113.
Cobleigh M, Yardley DA, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Hurvitz SA, O'Shaughnessy J, Mason G, Antao V, Li H, Chu L, Jahanzeb M. PMID: 31772121.
View in:
PubMed Mentions:
14 Fields:
Translation:
Humans
-
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist. 2020 03; 25(3):e439-e450.
Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. PMID: 32162822; PMCID: PMC7066700.
View in:
PubMed Mentions:
44 Fields:
Translation:
HumansCellsCTClinical Trials
-
Identifying tests related to breast cancer care in claims data. Breast J. 2020 06; 26(6):1227-1230.
Franc BL, Thombley R, Luo Y, Boscardin WJ, Rugo HS, Seidenwurm D, Dudley RA. PMID: 31736191; PMCID: PMC7304302.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Treatment of early-stage hormone receptor-positive breast cancer. Clin Adv Hematol Oncol. 2019 Nov; 17(11):596-599.
Rugo HS. PMID: 31851159.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectr. 2020 Feb; 4(1):pkz085.
Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W. PMID: 32337496; PMCID: PMC7050154.
View in:
PubMed Mentions:
15 Fields:
-
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 02; 25(2):e214-e222.
Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA. PMID: 32043771; PMCID: PMC7011632.
View in:
PubMed Mentions:
26 Fields:
Translation:
Humans
-
Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. Eur J Surg Oncol. 2020 02; 46(2):223-228.
Golshan M, Wong SM, Loibl S, Huober JB, O'Shaughnessy J, Rugo HS, Wolmark N, Ansell P, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE, Sikov WM, Untch M. PMID: 31606288.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer. Clin Adv Hematol Oncol. 2019 10; 17(10):555-558.
Rugo HS. PMID: 31730581.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. Clin Cancer Res. 2020 01 01; 26(1):110-121.
Finn RS, Liu Y, Zhu Z, Martin M, Rugo HS, Diéras V, Im SA, Gelmon KA, Harbeck N, Lu DR, Gauthier E, Huang Bartlett C, Slamon DJ. PMID: 31527167.
View in:
PubMed Mentions:
76 Fields:
Translation:
Humans
-
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clin Breast Cancer. 2020 04; 20(2):e173-e180.
Rugo HS, Finn RS, Gelmon K, Joy AA, Harbeck N, Castrellon A, Mukai H, Walshe JM, Mori A, Gauthier E, Lu DR, Bananis E, Martin M, Diéras V. PMID: 31836434.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCTClinical Trials
-
Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer. Clin Adv Hematol Oncol. 2019 Sep; 17(9):486-489.
Rugo HS. PMID: 31549968.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; 30(9):1514-1520.
Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ. PMID: 31250880.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansCTClinical Trials
-
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Breast J. 2020 03; 26(3):368-375.
Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ. PMID: 31448513; PMCID: PMC7155112.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):e251-e260.
Mahtani R, Holmes FA, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Vogel C, Breast Cancer Therapy Expert Group (BCTEG). PMID: 32139271.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz058.
Uno H, Schrag D, Kim DH, Tang D, Tian L, Rugo HS, Wei LJ. PMID: 32337484; PMCID: PMC7050006.
View in:
PubMed Mentions:
2 Fields:
-
Achieving Improved Survival Outcomes in Advanced Breast Cancer. N Engl J Med. 2019 07 25; 381(4):371-372.
Rugo HS. PMID: 31340099.
View in:
PubMed Mentions:
7 Fields:
Translation:
Humans
-
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol. 2019; 11:1758835919854238.
Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, Le MH, Coussens LM, Rugo HS. PMID: 31258629; PMCID: PMC6589951.
View in:
PubMed Mentions:
65
-
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist. 2019 12; 24(12):1514-1525.
Diéras V, Harbeck N, Joy AA, Gelmon K, Ettl J, Verma S, Lu DR, Gauthier E, Schnell P, Mori A, Rugo HS, Finn RS. PMID: 31217344; PMCID: PMC6975938.
View in:
PubMed Mentions:
25 Fields:
Translation:
Humans
-
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. NPJ Breast Cancer. 2019; 5:17.
Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ. PMID: 31240240; PMCID: PMC6570645.
View in:
PubMed Mentions:
10
-
Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. Breast Cancer Res Treat. 2019 Sep; 177(2):401-408.
Melisko ME, Assefa M, Hwang J, DeLuca A, Park JW, Rugo HS. PMID: 31172405.
View in:
PubMed Mentions:
13 Fields:
Translation:
HumansCTClinical Trials
-
View in:
PubMed Mentions:
12 Fields:
Translation:
Humans
-
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019 05 16; 380(20):1929-1940.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D, SOLAR-1 Study Group. PMID: 31091374.
View in:
PubMed Mentions:
987 Fields:
Translation:
HumansCTClinical Trials
-
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncol. 2019 Jul; 15(19):2211-2225.
Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J. PMID: 31074641; PMCID: PMC7466911.
View in:
PubMed Mentions:
11 Fields:
Translation:
HumansCTClinical Trials
-
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310.
Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM. PMID: 31004299.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies. Cancer Med. 2019 05; 8(5):2064-2073.
Schwartzberg L, Karthaus M, Rossi G, Rizzi G, Borroni ME, Rugo HS, Jordan K, Hansen V. PMID: 30968588; PMCID: PMC6536946.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications. Plast Reconstr Surg Glob Open. 2019 Apr; 7(4):e2188.
Mukhtar RA, Holland M, Sieber DA, Wen KW, Rugo HS, Kadin ME, Bean GR. PMID: 31321184; PMCID: PMC6554181.
View in:
PubMed Mentions:
5
-
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875.
Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP. PMID: 30939096; PMCID: PMC7587424.
View in:
PubMed Mentions:
110 Fields:
Translation:
HumansCTClinical Trials
-
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. J Natl Cancer Inst. 2019 04 01; 111(4):419-430.
Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS. PMID: 30032196; PMCID: PMC6449170.
View in:
PubMed Mentions:
37 Fields:
Translation:
HumansCTClinical Trials
-
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019 03 01; 30(3):397-404.
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. PMID: 30475950.
View in:
PubMed Mentions:
363 Fields:
Translation:
HumansCTClinical Trials
-
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019 03 01; 30(3):405-411.
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. PMID: 30475947.
View in:
PubMed Mentions:
290 Fields:
Translation:
HumansCTClinical Trials
-
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019 02 21; 380(8):741-751.
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. PMID: 30786188.
View in:
PubMed Mentions:
340 Fields:
Translation:
HumansCTClinical Trials
-
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069.
Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium. PMID: 32031889; PMCID: PMC7106976.
View in:
PubMed Mentions:
49 Fields:
Translation:
HumansCTClinical Trials
-
NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019 02; 17(2):118-126.
Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R. PMID: 30787125.
View in:
PubMed Mentions:
88 Fields:
Translation:
Humans
-
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2019 02 01; 5(2):e184475.
Juric D, Janku F, Rodón J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, Quadt C, Rugo HS. PMID: 30543347; PMCID: PMC6439561.
View in:
PubMed Mentions:
114 Fields:
Translation:
HumansCTClinical Trials
-
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat. 2019 May; 175(1):5-15.
Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, Bosserman L. PMID: 30671765; PMCID: PMC6491395.
View in:
PubMed Mentions:
30 Fields:
Translation:
Humans
-
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019 Apr; 174(3):719-729.
Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. PMID: 30632023; PMCID: PMC6438948.
View in:
PubMed Mentions:
170 Fields:
Translation:
HumansCTClinical Trials
-
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 04 15; 25(8):2433-2441.
Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M. PMID: 30593513.
View in:
PubMed Mentions:
45 Fields:
Translation:
Humans
-
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res. 2019 05 01; 25(9):2717-2724.
Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME, ABRAZO Study Group. PMID: 30563931.
View in:
PubMed Mentions:
66 Fields:
Translation:
HumansCTClinical Trials
-
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2019 02 01; 37(4):318-327.
Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK. PMID: 30557521.
View in:
PubMed Mentions:
442 Fields:
Translation:
HumansCellsCTClinical Trials
-
Demystifying biosimilars: development, regulation and clinical use. Future Oncol. 2019 Mar; 15(7):777-790.
Rugo HS, Rifkin RM, Declerck P, Bair AH, Morgan G. PMID: 30500264.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clin Pharmacol Ther. 2019 03; 105(3):738-745.
Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL. PMID: 30260474; PMCID: PMC6379108.
View in:
PubMed Mentions:
7 Fields:
Translation:
HumansCTClinical Trials
-
Geographic and Patient Characteristics Associated With Election of Prophylactic Mastectomy in Young Breast Cancer Patients With Early Disease. Am J Clin Oncol. 2018 Nov; 41(11):1037-1042.
Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean M, Boscardin WJ, Rugo HS, Dudley RA. PMID: 32463216.
View in:
PubMed Mentions:
3 Fields:
-
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. Eur J Cancer. 2018 11; 104:160-168.
Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balmaña J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM. PMID: 30359909.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCellsCTClinical Trials
-
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 11 29; 379(22):2108-2121.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Trial Investigators. PMID: 30345906.
View in:
PubMed Mentions:
1919 Fields:
Translation:
HumansCTClinical Trials
-
Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ Breast Cancer. 2018; 4:31.
Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW. PMID: 30211312; PMCID: PMC6125436.
View in:
PubMed Mentions:
17
-
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 09 01; 29(9):1939-1947.
Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. PMID: 30124753.
View in:
PubMed Mentions:
68 Fields:
Translation:
HumansCTClinical Trials
-
Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. Am J Cancer Res. 2018; 8(9):1873-1886.
Li H, Xu Y, Zhao F, Song G, Rugo HS, Zhang Y, Yang L, Liu X, Shao B, Yang L, Liu Y, Ran R, Zhang R, Guan Y, Chang L, Yi X. PMID: 30323979; PMCID: PMC6176180.
View in:
PubMed Mentions:
6
-
Advance Care Planning in Community: An Evaluation of a Pilot 2-Session, Nurse-Led Workshop. Am J Hosp Palliat Care. 2019 Feb; 36(2):143-146.
Rabow MW, McGowan M, Small R, Keyssar R, Rugo HS. PMID: 30153741.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 08 23; 379(8):753-763.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. PMID: 30110579; PMCID: PMC10600918.
View in:
PubMed Mentions:
873 Fields:
Translation:
HumansCTClinical Trials
-
Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. Clin Breast Cancer. 2018 12; 18(6):489-497.
Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L. PMID: 30153978.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCTClinical Trials
-
Highlights in breast cancer from the 2018 American Society of Clinical Oncology annual meeting. Clin Adv Hematol Oncol. 2018 Aug; 16(8):533-537.
Rugo HS. PMID: 30148824.
View in:
PubMed Mentions: Fields:
-
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018 08 01; 29(8):1634-1657.
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. PMID: 30032243; PMCID: PMC7360146.
View in:
PubMed Mentions:
472 Fields:
Translation:
Humans
-
Circulating Tumors Cells as a Biomarker of Radiation Benefit. JAMA Oncol. 2018 08 01; 4(8):e180194.
Speers C, Rugo HS. PMID: 29800965.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Reply to the letter to the editor 'Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analyses' by Kaiser et al. Ann Oncol. 2018 08 01; 29(8):1878.
Rugo HS, Iyer S, Huang C. PMID: 29873677.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018 09; 101:123-133.
Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S. PMID: 30053671.
View in:
PubMed Mentions:
35 Fields:
Translation:
Humans
-
The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia. Future Oncol. 2018 Oct; 14(24):2461-2469.
Mustoe MM, Lee CM, Melisko ME, Esserman LJ, Rugo HS. PMID: 30001151.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer. J Natl Compr Canc Netw. 2018 07; 16(7):829-837.
Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA. PMID: 30006425.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 10 01; 24(19):4734-4744.
Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL. PMID: 29871907; PMCID: PMC6168379.
View in:
PubMed Mentions:
11 Fields:
Translation:
HumansCells
-
Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chin J Cancer Res. 2018 Jun; 30(3):315-326.
Liu X, Ran R, Shao B, Rugo HS, Yang Y, Hu Z, Wei Z, Wan F, Kong W, Song G, Jiang H, Liang X, Zhang R, Yan Y, Xu G, Li H. PMID: 30046226; PMCID: PMC6037585.
View in:
PubMed Mentions:
12
-
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Res Treat. 2018 Aug; 170(3):547-557.
O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS. PMID: 29675680.
View in:
PubMed Mentions:
22 Fields:
Translation:
HumansCTClinical Trials
-
The new world of biosimilars in oncology: Translation of data to the clinic. Eur J Cancer. 2018 06; 96:125-127.
Rugo HS, Cortes J. PMID: 29680363.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clin Cancer Res. 2018 07 15; 24(14):3348-3357.
Rugo HS, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri M, Hoch U, Perez EA. PMID: 29618616.
View in:
PubMed Mentions:
11 Fields:
Translation:
HumansCells
-
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018 04 01; 29(4):888-894.
Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. PMID: 29360932; PMCID: PMC5913649.
View in:
PubMed Mentions:
75 Fields:
Translation:
HumansCTClinical Trials
-
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clin Cancer Res. 2018 06 15; 24(12):2804-2811.
Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR. PMID: 29559561.
View in:
PubMed Mentions:
180 Fields:
Translation:
HumansCellsCTClinical Trials
-
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs. 2018 03; 29(3):271-280.
Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, Finn RS, Joy AA, Ettl J, Rugo HS, Zheng J, Wilner KD, Wang DD. PMID: 29360661; PMCID: PMC5821476.
View in:
PubMed Mentions:
18 Fields:
Translation:
HumansCTClinical Trials
-
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 04; 19(4):497-509.
Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE. PMID: 29501363.
View in:
PubMed Mentions:
300 Fields:
Translation:
HumansCTClinical Trials
-
Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. J Am Dent Assoc. 2018 04; 149(4):291-298.
Chambers MS, Rugo HS, Litton JK, Meiller TF. PMID: 29439772.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol. 2018 05 01; 36(13):1291-1299.
Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. PMID: 29401002; PMCID: PMC5920739.
View in:
PubMed Mentions:
191 Fields:
Translation:
HumansCTClinical Trials
-
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Res Treat. 2018 May; 169(1):1-7.
Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C. PMID: 29352368; PMCID: PMC5882621.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell. 2018 01 08; 33(1):60-74.e6.
de Mingo Pulido Á, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM, Ruffell B. PMID: 29316433; PMCID: PMC5764109.
View in:
PubMed Mentions:
182 Fields:
Translation:
HumansAnimalsCells
-
Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clin Cancer Res. 2018 03 15; 24(6):1486-1499.
Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, Hyslop T, Barry WT, Isakoff SJ, Dickler M, Van't Veer L, Park JW. PMID: 29311117; PMCID: PMC5856614.
View in:
PubMed Mentions:
24 Fields:
Translation:
HumansCells
-
Emerging data on improving response to hormone therapy: the role of novel targeted agents. Expert Rev Anticancer Ther. 2018 01; 18(1):3-18.
Vidula N, Rugo HS. PMID: 29192520.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 12; 15(12):1520-1541.
Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L. PMID: 29223990.
View in:
PubMed Mentions:
66 Fields:
Translation:
HumansCells
-
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017 12 01; 28(12):3111.
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. PMID: 28327998; PMCID: PMC5834023.
View in:
PubMed Mentions:
47 Fields:
-
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017 Dec 20; 35(36):4035-4041.
Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A. PMID: 29095678.
View in:
PubMed Mentions:
223 Fields:
Translation:
HumansCTClinical Trials
-
Real-world use of scalp cooling to reduce chemotherapy-related hair loss. Clin Adv Hematol Oncol. 2017 Nov; 15(11):828-831.
Rugo HS. PMID: 29200414.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017 11; 166(1):327-328.
Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J. PMID: 28884461; PMCID: PMC6828475.
View in:
PubMed Mentions: Fields:
-
Dual HER2 Blockade. Breast Care (Basel). 2017 Oct; 12(5):345-349.
Thomssen C, El Saghir NS, Francis PA, Jassem J, Rugo HS, Untch M. PMID: 29234257; PMCID: PMC5704717.
View in:
PubMed Mentions:
-
The value of embedding: integrated palliative care for patients with metastatic breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):703-708.
Rabow M, Small R, Jow A, Majure M, Chien A, Melisko M, Belkora J, Esserman LJ, Rugo H. PMID: 29086230.
View in:
PubMed Mentions:
11 Fields:
Translation:
HumansCTClinical Trials
-
Use of Neoadjuvant Platinum-The Ongoing Conundrum. JAMA Oncol. 2017 10 01; 3(10):1312-1314.
Rugo HS, Gelmon K. PMID: 28715579.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2018 01; 167(1):117-122.
Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME. PMID: 28921303.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansAnimalsCTClinical Trials
-
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017; 3:31.
Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. PMID: 28948212; PMCID: PMC5572474.
View in:
PubMed Mentions:
45
-
Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. Cancer Res. 2017 08 15; 77(16):4530-4541.
Gulbahce N, Magbanua MJM, Chin R, Agarwal MR, Luo X, Liu J, Hayden DM, Mao Q, Ciotlos S, Li Z, Chen Y, Chen X, Li Y, Zhang RY, Lee K, Tearle R, Park E, Drmanac S, Rugo HS, Park JW, Drmanac R, Peters BA. PMID: 28811315.
View in:
PubMed Mentions:
26 Fields:
Translation:
HumansCells
-
Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Breast Cancer. 2018 02; 18(1):19-28.
Rugo HS, Voigt J. PMID: 28939291.
View in:
PubMed Mentions:
22 Fields:
Translation:
Humans
-
Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach? J Clin Oncol. 2017 09 20; 35(27):3089-3091.
Chien AJ, Rugo HS. PMID: 28783451.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 08; 165(1):161.
Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. PMID: 28660429.
View in:
PubMed Mentions:
1 Fields:
-
Highlights in breast cancer from the 2017 American Society of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol. 2017 Aug; 15(8):607-614.
Rugo HS. PMID: 28949948.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer-Reply. JAMA Oncol. 2017 08 01; 3(8):1142.
Melisko ME, Hwang J, Rugo HS. PMID: 28727874.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol. 2017 Aug 01; 3(8):1043-1050.
Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. PMID: 28208174; PMCID: PMC5553624.
View in:
PubMed Mentions:
59 Fields:
Translation:
HumansCTClinical Trials
-
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. Breast Cancer Res Treat. 2017 Oct; 165(3):601-609.
Rugo HS, Trédan O, Ro J, Morales SM, Campone M, Musolino A, Afonso N, Ferreira M, Park KH, Cortes J, Tan AR, Blum JL, Eaton L, Gause CK, Wang Z, Im E, Mauro DJ, Jones MB, Denker A, Baselga J. PMID: 28681171; PMCID: PMC5709225.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCTClinical Trials
-
NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017 07; 15(7):883-893.
Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M. PMID: 28687576.
View in:
PubMed Mentions:
74 Fields:
Translation:
Humans
-
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J. 2017 09; 19(5):1411-1423.
Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV. PMID: 28620884; PMCID: PMC5711539.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCTClinical Trials
-
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017 Sep; 165(2):329-341.
Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J. PMID: 28612225; PMCID: PMC5543189.
View in:
PubMed Mentions:
19 Fields:
-
Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):129-138.
Vidula N, Yau C, Li J, Esserman LJ, Rugo HS. PMID: 28577080; PMCID: PMC5725604.
View in:
PubMed Mentions:
10 Fields:
Translation:
HumansCTClinical Trials
-
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5218-5224.
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. PMID: 28533223; PMCID: PMC5581697.
View in:
PubMed Mentions:
282 Fields:
Translation:
HumansCTClinical Trials
-
Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 Aug; 165(1):151-159.
Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. PMID: 28503722.
View in:
PubMed Mentions:
27 Fields:
Translation:
HumansCTClinical Trials
-
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017 Aug 01; 35(22):2535-2541.
Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC. PMID: 28489510.
View in:
PubMed Mentions:
207 Fields:
Translation:
HumansCTClinical Trials
-
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. Eur J Cancer. 2017 05; 76:205-215.
Twelves C, Cortés J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS. PMID: 28360015.
View in:
PubMed Mentions:
6 Fields:
Translation:
HumansCTClinical Trials
-
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2017 06; 163(3):535-544.
Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS. PMID: 28324268; PMCID: PMC5448790.
View in:
PubMed Mentions:
9 Fields:
Translation:
HumansCTClinical Trials
-
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017 05; 18(5):654-662.
Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK. PMID: 28314691.
View in:
PubMed Mentions:
73 Fields:
Translation:
HumansCTClinical Trials
-
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 07 08; 67(4):290-303.
Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN. PMID: 28294295.
View in:
PubMed Mentions:
363 Fields:
Translation:
Humans
-
Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. Breast. 2017 Jun; 33:76-82.
Rugo HS, Rossi G, Rizzi G, Aapro M. PMID: 28285236.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Res Treat. 2017 Jun; 163(2):199-205.
Rugo HS, Melin SA, Voigt J. PMID: 28275922; PMCID: PMC5410200.
View in:
PubMed Mentions:
26 Fields:
Translation:
Humans
-
Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017 Mar 01; 3(3):313-319.
Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS. PMID: 27832260.
View in:
PubMed Mentions:
33 Fields:
Translation:
HumansCTClinical Trials
-
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017 02 14; 317(6):606-614.
Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T. PMID: 28196257; PMCID: PMC5639721.
View in:
PubMed Mentions:
49 Fields:
Translation:
Humans
-
Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. Breast. 2017 04; 32:269-270.
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. PMID: 28109648.
View in:
PubMed Mentions: Fields:
-
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA. 2017 01 03; 317(1):37-47.
Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, Sharma R, Baczkowski M, Kothekar M, Loganathan S, Manikhas A, Bondarenko I, Mukhametshina G, Nemsadze G, Parra JD, Abesamis-Tiambeng ML, Baramidze K, Akewanlop C, Vynnychenko I, Sriuranpong V, Mamillapalli G, Ray S, Yanez Ruiz EP, Pennella E, Heritage Study Investigators. PMID: 27918780.
View in:
PubMed Mentions:
65 Fields:
Translation:
HumansCTClinical Trials
-
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017 01 01; 28(1):16-33.
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. PMID: 28177437; PMCID: PMC5378224.
View in:
PubMed Mentions:
181 Fields:
Translation:
Humans
-
Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer. Adv Exp Med Biol. 2017; 1026:403-418.
Rugo HS, Li H, Gui X. PMID: 29282695.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 2017 Feb; 31:244-259.
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. PMID: 27927580.
View in:
PubMed Mentions:
81 Fields:
Translation:
Humans
-
Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. Curr Opin Support Palliat Care. 2016 12; 10(4):336-342.
Dawood S, Rugo HS. PMID: 27755140.
View in:
PubMed Mentions:
6 Fields:
Translation:
Humans
-
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer. 2017 04; 25(4):1127-1135.
Aapro M, Karthaus M, Schwartzberg L, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Hansen V, Rossi G, Rizzi G, Borroni ME, Rugo H. PMID: 27885469; PMCID: PMC5321708.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCTClinical Trials
-
Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 11 17; 375(20):1925-1936.
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. PMID: 27959613.
View in:
PubMed Mentions:
1127 Fields:
Translation:
HumansCTClinical Trials
-
NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. J Natl Compr Canc Netw. 2016 11; 14(11):1357-1370.
VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, Edil BH, Edwards B, Extermann M, Ganti AK, Gross C, Hubbard J, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Shepard D, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Wildes T, Bergman MA, Sundar H, Hurria A. PMID: 27799507.
View in:
PubMed Mentions:
41 Fields:
Translation:
Humans
-
When to Treat, With What, and for How Long: That Is the Question! J Oncol Pract. 2016 11; 12(11):1160-1162.
Dawood S, Rugo HS. PMID: 27858543.
View in:
PubMed Mentions: Fields:
-
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med. 2016 11; 22(11):1321-1329.
Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A. PMID: 27775705; PMCID: PMC5341692.
View in:
PubMed Mentions:
92 Fields:
Translation:
HumansAnimalsCells
-
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. Springerplus. 2016; 5(1):1033.
Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, O'Shaughnessy J. PMID: 27441152; PMCID: PMC4938835.
View in:
PubMed Mentions:
4
-
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators. PMID: 27406347; PMCID: PMC5259561.
View in:
PubMed Mentions:
237 Fields:
Translation:
HumansCTClinical Trials
-
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Oncologist. 2016 10; 21(10):1165-1175.
Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, Cristofanilli M, Zhang K, Thiele A, Turner NC, Rugo HS. PMID: 27368881; PMCID: PMC5061543.
View in:
PubMed Mentions:
99 Fields:
Translation:
HumansCTClinical Trials
-
Highlights in breast cancer from the 2016 American Society of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol. 2016 Jul; 14(7):494-7.
Rugo HS. PMID: 27379943.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016 08; 5(8):1897-907.
Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, Campbell-Baird C, Hronek J, Seery V, Divers J, Glaspy J, Schmidt BL, Meiller TF. PMID: 27334013; PMCID: PMC4971919.
View in:
PubMed Mentions:
22 Fields:
Translation:
Humans
-
Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget. 2016 Jun 21; 7(25):38359-38366.
Morrison G, Lenkala D, LaCroix B, Ziliak D, Abramson V, Morrow PK, Forero A, Van Poznak C, Rugo HS, Nanda R, O'Donnell PH, Huang RS. PMID: 27224917; PMCID: PMC5122395.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 09 01; 34(25):3069-103.
Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ. PMID: 27217461.
View in:
PubMed Mentions:
261 Fields:
Translation:
Humans
-
Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little. J Clin Oncol. 2016 07 01; 34(19):2203-5.
Wolff AC, Rugo HS. PMID: 27185850.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 08 01; 34(22):2602-9.
Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. PMID: 27138575; PMCID: PMC5012690.
View in:
PubMed Mentions:
50 Fields:
Translation:
HumansCTClinical Trials
-
A clinician's guide to biosimilars in oncology. Cancer Treat Rev. 2016 May; 46:73-9.
Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I. PMID: 27135548.
View in:
PubMed Mentions:
22 Fields:
Translation:
Humans
-
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30.
Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
View in:
PubMed Mentions:
19 Fields:
Translation:
HumansCTClinical Trials
-
Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78.
Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. PMID: 26868124.
View in:
PubMed Mentions:
13 Fields:
Translation:
Humans
-
HER2-positive breast cancer: is more treatment better? Lancet Oncol. 2016 Mar; 17(3):268-270.
Rugo HS, Chien AJ. PMID: 26874902.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol. 2016 Mar; 27(3):519-25.
Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, Ringeisen F, Gallo J, Rouyrre N, Anak O, Motzer R. PMID: 26759276; PMCID: PMC4769991.
View in:
PubMed Mentions:
37 Fields:
Translation:
Humans
-
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36.
Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM. PMID: 26539793; PMCID: PMC5654518.
View in:
PubMed Mentions:
46 Fields:
Translation:
Humans
-
Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. Am Soc Clin Oncol Educ Book. 2016; 35:e40-54.
Rugo HS, Vidula N, Ma C. PMID: 27249746.
View in:
PubMed Mentions:
24 Fields:
Translation:
Humans
-
Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Ther Adv Med Oncol. 2015 Nov; 7(6):321-39.
Jiang H, Rugo HS. PMID: 26557900; PMCID: PMC4622301.
View in:
PubMed Mentions:
18
-
Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015 Nov; 154(2):339-49.
Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW. PMID: 26520840.
View in:
PubMed Mentions:
33 Fields:
Translation:
HumansCells
-
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol. 2016 Feb 10; 34(5):419-26.
Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J. PMID: 26503204; PMCID: PMC5070556.
View in:
PubMed Mentions:
114 Fields:
Translation:
Humans
-
A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One. 2015; 10(10):e0141166.
Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A, Rugo HS, Park JW. PMID: 26496203; PMCID: PMC4619669.
View in:
PubMed Mentions:
8 Fields:
Translation:
HumansCells
-
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015 Nov; 16(15):1556-1568.
Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J. PMID: 26482278.
View in:
PubMed Mentions:
30 Fields:
Translation:
HumansCTClinical Trials
-
Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer. Clin Breast Cancer. 2016 Feb; 16(1):18-22.
Rugo HS. PMID: 26507507.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int. 2015; 2015:651879.
Hesketh PJ, Aapro M, Jordan K, Schwartzberg L, Bosnjak S, Rugo H. PMID: 26421300; PMCID: PMC4573229.
View in:
PubMed Mentions:
7 Fields:
Translation:
Humans
-
Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw. 2015 Aug; 13(8):1012-39.
Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS, Salvador C, Wagner LI, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C, National comprehensive cancer network. PMID: 26285247; PMCID: PMC5499710.
View in:
PubMed Mentions:
313 Fields:
Translation:
Humans
-
Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clin Breast Cancer. 2016 Feb; 16(1):8-17.
Vidula N, Rugo HS. PMID: 26303211.
View in:
PubMed Mentions:
43 Fields:
Translation:
Humans
-
Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81.
Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. PMID: 26208485.
View in:
PubMed Mentions:
8 Fields:
Translation:
Humans
-
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. PMID: 26211600; PMCID: PMC5365030.
View in:
PubMed Mentions:
56 Fields:
Translation:
Humans
-
The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Manag Res. 2015; 7:175-88.
Palli SR, Grabner M, Quimbo RA, Rugo HS. PMID: 26124681; PMCID: PMC4476437.
View in:
PubMed Mentions:
5
-
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015 Jul 20; 33(21):2361-9.
Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. PMID: 26056183; PMCID: PMC4500830.
View in:
PubMed Mentions:
109 Fields:
Translation:
HumansCTClinical Trials
-
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015 May 29; 17:73.
Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, I-SPY 1 TRIAL Investigators, Esserman L, Park JW, van 't Veer LJ. PMID: 26021444; PMCID: PMC4479083.
View in:
PubMed Mentions:
44 Fields:
Translation:
HumansCells
-
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96.
Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. PMID: 25981899; PMCID: PMC5057177.
View in:
PubMed Mentions:
24 Fields:
Translation:
Humans
-
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015 Jun 10; 33(17):1902-9.
Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. PMID: 25847936; PMCID: PMC4451173.
View in:
PubMed Mentions:
195 Fields:
Translation:
HumansCTClinical Trials
-
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Res Treat. 2015 Apr; 150(3):605-11.
Lohmann AE, Chapman JA, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O'Brien P, Han L, Rugo HS, Albain KS, Perez EA, Vandenberg TA, Chalchal HI, Sawhney RP, Shepherd LE, Goodwin PJ. PMID: 25833209.
View in:
PubMed Mentions:
9 Fields:
Translation:
HumansCTClinical Trials
-
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2722-9.
Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC, Translational Breast Cancer Research Consortium (TBCRC). PMID: 25779953; PMCID: PMC6186432.
View in:
PubMed Mentions:
37 Fields:
Translation:
HumansCTClinical Trials
-
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; 121(12):1937-48.
Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. PMID: 25757412; PMCID: PMC4457605.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2015 Mar; 13(3 Suppl 3):3-13, 1; quiz 2 p following 14.
Schwartzberg LS, Rugo HS, Aapro MS. PMID: 25856052.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5.
DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. PMID: 25712686; PMCID: PMC4490043.
View in:
PubMed Mentions:
44 Fields:
Translation:
Humans
-
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41.
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. PMID: 25564897; PMCID: PMC4313867.
View in:
PubMed Mentions:
251 Fields:
Translation:
HumansCTClinical Trials
-
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Res Treat. 2015 Jan; 149(2):439-48.
Liu S, Chapman JA, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, Barry G, Gao D, O'Brien P, Shepherd LE, Nielsen TO, Gelmon KA. PMID: 25552364.
View in:
PubMed Mentions:
14 Fields:
Translation:
HumansCTClinical Trials
-
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol. 2015 Feb 01; 33(4):340-8.
Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. PMID: 25534386; PMCID: PMC4302215.
View in:
PubMed Mentions:
56 Fields:
Translation:
Humans
-
Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res. 2015 Mar 01; 21(5):1098-105.
Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS, Translational Breast Cancer Research Consortium. PMID: 25524311.
View in:
PubMed Mentions:
25 Fields:
Translation:
HumansCells
-
SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer. Cancer. 2015 Mar 15; 121(6):893-9.
Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman LJ, Melisko ME. PMID: 25469673.
View in:
PubMed Mentions:
29 Fields:
Translation:
Humans
-
Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting. Clin Ther. 2015 Jan 01; 37(1):134-44.
Dranitsaris G, Gluck S, Faria C, Cox D, Rugo H. PMID: 25433768.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Translating the molecular message of triple-negative breast cancer into targeted therapy. Clin Cancer Res. 2015 Apr 01; 21(7):1511-3.
Vidula N, Rugo HS. PMID: 25351747.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014 Dec 01; 32(34):3840-7.
O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP. PMID: 25349301.
View in:
PubMed Mentions:
119 Fields:
Translation:
HumansCTClinical Trials
-
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014 Nov 10; 26(5):623-37.
Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM. PMID: 25446896; PMCID: PMC4254570.
View in:
PubMed Mentions:
504 Fields:
Translation:
HumansAnimalsCells
-
A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. Breast Cancer Res Treat. 2014 Nov; 148(1):99-106.
Miller KD, Althouse SK, Nabell L, Rugo H, Carey L, Kimmick G, Jones DR, Merino MJ, Steeg PS. PMID: 25257727; PMCID: PMC8374454.
View in:
PubMed Mentions:
12 Fields:
Translation:
HumansCTClinical Trials
-
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014 Oct; 23(5):489-502.
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E, European School of Oncology, European Society of Medical Oncology. PMID: 25244983.
View in:
PubMed Mentions:
124 Fields:
Translation:
Humans
-
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 2014 Oct; 25(10):1871-1888.
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. PMID: 25234545; PMCID: PMC4176456.
View in:
PubMed Mentions:
136 Fields:
Translation:
Humans
-
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol. 2014 Dec; 25(12):2357-2362.
Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J. PMID: 25231953; PMCID: PMC6267855.
View in:
PubMed Mentions:
227 Fields:
Translation:
HumansCTClinical Trials
-
Practice patterns in the delivery of radiation therapy after mastectomy among the University of California Athena Breast Health Network. Clin Breast Cancer. 2015 Feb; 15(1):43-7.
Mayadev J, Einck J, Elson S, Rugo H, Hwang S, Bold R, Daroui P, McCloskey S, Yashar C, Kim D, Fowble B. PMID: 25245425.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia. 2014 Aug; 30(5):285-94.
Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O'Connor B, Myerson R, Stauffer P, Hsu IC, Diederich C, Straube W, Boss MK, Boico A, Craciunescu O, Maccarini P, Needham D, Borys N, Blackwell KL, Dewhirst MW. PMID: 25144817; PMCID: PMC4162656.
View in:
PubMed Mentions:
37 Fields:
Translation:
HumansCTClinical Trials
-
Reply to the letter to the editor 'Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer' Tannock and Pond. Ann Oncol. 2014 Oct; 25(10):2096-2098.
Rugo HS, Aapro M. PMID: 25085504.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer. Clin Adv Hematol Oncol. 2014 Aug; 12(8 Suppl 15):3-21; quiz 22.
Gradishar WJ, Twelves C, Rugo HS. PMID: 25768893.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Hormone therapy in premenopausal women with early-stage breast cancer. N Engl J Med. 2014 Jul 10; 371(2):175-6.
Rugo HS. PMID: 25006724.
View in:
PubMed Mentions:
5 Fields:
Translation:
Humans
-
The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 2014 Jul 17; 511(7509):319-25.
Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM. PMID: 25030168; PMCID: PMC4487551.
View in:
PubMed Mentions:
310 Fields:
Translation:
HumansAnimalsCells
-
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer. 2014 Sep 01; 120(17):2657-64.
Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Yoo B, Brammer MG, Vogel CL. PMID: 24930388; PMCID: PMC4232097.
View in:
PubMed Mentions:
23 Fields:
Translation:
Humans
-
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50.
Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. PMID: 24888816; PMCID: PMC4076026.
View in:
PubMed Mentions:
95 Fields:
Translation:
Humans
-
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer. 2014 May 02; 14:307.
Tripathy D, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S. PMID: 2488